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Abstract 
Subharmonic Aided Pressure Estimation for Monitoring Interstitial Fluid Pressure in 
Tumors 
Valgerður Guðrún Halldórsdóttir 
Flemming Forsberg, PhD and Peter A. Lewin PhD supervisors 
 
 
 
 
 The purpose of this study is to evaluate whether the ultrasound contrast agent 
based method subharmonic aided pressure estimation (SHAPE) can be used to measure 
the interstitial fluid pressure in locally advanced breast cancer thereby allowing for 
noninvasive monitoring of tumor response to neoadjuvant chemotherapy.  
Vascular ultrasound contrast agents (UCAs) are gas-filled microbubbles that 
improve the depiction of vascularity in ultrasound (US) images by enhancing the 
difference in reflectivity between tissue and the agent. At higher acoustic outputs (> 200 
kPa) contrast agents act as nonlinear oscillators producing harmonics, ultra- and 
subharmonics in the received signals. In subharmonic imaging (SHI) pulses are 
transmitted at a frequency f0 and the echoes are received at half that frequency (f0/2). SHI 
has been shown to be a feasible option for contrast enhanced breast imaging due to 
marked subharmonic generation by the bubbles relative to limited subharmonic 
generation in tissues. A novel technique, subharmonic aided pressure estimation or 
SHAPE, utilizing the subharmonic amplitude of the scattered signal from the 
xx 
 
microbubbles for pressure tracking was developed by our group and has been 
implemented for various applications such as cardiac and hepatic pressure measurements.  
 It has been hypothesized that the level of interstitial fluid pressure (IFP) in a 
breast cancer tumor can be used to predict the response to systemic preoperative therapy. 
Thus, tumors with high IFP should show a poorer response to therapy than those with low 
IFP [2]. We propose that by using SHAPE the IFP of locally advanced breast cancer 
tumors can be estimated noninvasively in order to monitor the response to systemic 
preoperative chemotherapy. This method would be a considerable improvement from the 
wick-in-needle method currently used for IFP measurements as it is noninvasive and 
would thus potentially increase the use of IFP as a biomarker for neoadjuvant 
chemotherapy. 
 The possibility of using SHAPE to noninvasively estimate IFP was studied both 
in vitro and in vivo. In vitro an inverse linear relationship between hydrostatic pressure 
and subharmonic amplitude was observed with r
2
 = 0.63–0.95; p < 0.05, maximum 
amplitude drop 11.36 dB at 10 MHz and 8 dB, and r
2
 as high as 0.97; p < 0.02 (10 MHz 
transmit frequency and -4/-8 dB acoustic output power most promising), indicating that 
SHAPE may be useful in monitoring IFP. Moreover, in vivo proof-of-concept for SHAPE 
as a noninvasive monitor of IFP was provided in four swine with naturally occurring 
melanoma. SHAPE showed excellent correlation with IFP values obtained in normal 
tissues and in the tumor compared to  needle-based pressure measurements (r
2
 = 0.67 – 
0.96, p < 0.01) with optimal sensitivity for SHAPE at a transmission frequency of 10 
MHz and acoustic output settings -4 or -8 dB. Further studies in a murine model with 
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human breast cancer xenografts showed correlations (r: -0.60 to -0.74, p < 0.01) between 
IFP in tumor and tissue and subharmonic amplitude. Results suggested that calibration 
curves can be used to noninvasively estimate IFP using subharmonic data  such that there 
is no statistically significant difference between the calculated and measured groups at a 
115% threshold (p > 0.14). These results strongly indicate the feasibility of using SHAPE 
as a noninvasive pressure monitor of IFP in tumors.
1 
1 INTRODUCTION 
1.1 Overview 
 In the United States 5 – 20 % of newly diagnosed breast cancers and 10 – 30 % of 
all primary breast cancers are diagnosed as locally advanced breast cancer (LABC) [3, 4]. 
Systemic preoperative therapy (so called neoadjuvant chemotherapy) is the standard of 
care for the treatment of LABC [5, 6]. Studies have shown that it is as efficient as surgery 
when assessed by disease-free and overall survival [7]. In addition, it offers considerable 
benefits to patients, such as reduced tumor size at the time of surgery and a greater 
chance of breast conservation and reconstruction [5, 8-10]. By monitoring the treatment it 
is possible to predict the patient response to chemotherapy early on and use that 
information to optimize the treatment [5, 9]. Currently, extensive research is being 
conducted on monitoring techniques for systemic preoperative therapy. One of the 
biomarkers suggested is the interstitial fluid pressure (IFP) in breast cancers that could 
potentially be measured and used to monitor the response to neoadjuvant chemotherapy  
[11]. 
 Generally IFP is 10-30 mmHg higher in cancerous tissue than in normal tissue 
although values of up to 60 mmHg have been recorded [12, 13]. Similarly, IFP in breast 
cancers has been shown to be higher than that of surrounding breast tissue [13]. This 
increase is believed to be due to vascularity, fibrosis and difference in the interstitial 
matrix in tumors and it can result in poor transport of therapeutic drugs to tumors [12]. 
Taghian et al. used a wick-in-needle technique to monitor the IFP of breast cancer before 
and after neoadjuvant chemotherapy with two drugs used consecutively [2]. When used 
2 
as a first drug paclitaxel decreased the IFP by 36% (p=0.02). As this was a hypothesis-
generating study the investigators did not demonstrate any outcome related to the 
relationship between IFP and therapy response [2]. However, the level of IFP has been 
shown to predict disease free survival (DFS) for cervical cancer The reference standard 
for IFP measurements is a wick in needle method that is invasive and could possibly 
introduce needle track seeding of cancer cells into healthy tissue. Thus, an improved 
method of IFP measurement is needed if this marker is to become useful in clinical 
practice. 
 Vascular ultrasound contrast agents (UCA) are gas-filled microbubbles (diameter 
generally less than 8 µm) that improve the depiction of vascularity in ultrasound (US) 
images by enhancing the difference in reflectivity between tissue and the agent [14]. Due 
to their small size, these microbubbles can enter capillaries throughout the body [14]. 
Given the difference in compressibility between the surrounding medium and a gas 
microbubble any changes in hydrostatic pressure induce changes in the size of the 
microbubble [1]. This in turn affects the reflectivity and resonance frequency of the 
bubble [1, 15]. Furthermore, UCAs can act as nonlinear oscillators producing harmonics 
in the received signals. In SHI pulses are transmitted at a frequency f0 and the echoes are 
received at half that frequency (f0/2) [1, 16].  
 We suggest that subharmonic-aided pressure estimation (SHAPE), a method 
utilizing UCAs, can be used to estimate the IFP in LABC tumors, thereby, allowing the 
tumor response to chemotherapy to be monitored. This method would be a considerable 
improvement over the wick-in-needle method currently used sparingly for IFP 
measurements as it is safe and noninvasive and would thus, potentially increase the use of 
3 
IFP as a biomarker for neoadjuvant chemotherapy. Finally, it will make it easier to 
customize patient treatment by enabling monitoring of treatment response. 
1.2 Thesis Objectives  
 Subharmonic aided pressure estimation (SHAPE) is a novel US  based technique 
that utilizes the subharmonic amplitude of the scattered signal from microbubbles for 
pressure tracking [1]. Our group has proposed that SHAPE can be used to measure the 
IFP in LABC. By noninvasively estimating IFP it would be possible to monitor the tumor 
response to neoadjuvant chemotherapy. In order to evaluate SHAPE for tumor pressure 
estimation the following specific aims and hypotheses have been put forward: 
Specific aim 1: To determine if the UCA Definity (Lantheus Medical Imaging, N 
Billerica, MA) can be used for pressure estimation in vitro. The optimal acoustic 
parameters for SHAPE; acoustic output and transmit/receive frequency, will be 
established via in vitro measurements using a commercial US scanner in a water-tank. 
The parameters that result in the greatest change in subharmonic signal amplitude over a 
change in hydrostatic pressure from 0 to 50 mmHg (simulating IFP in tumors) will be 
used for the in vivo measurements in specific aims 3-4.  
Hypothesis 1: A significant (p ≤ 0.05) inverse linear relationship between hydrostatic 
pressure and subharmonic amplitude with an |r|-value above 0.9 can be obtained in vitro. 
 
Specific aim 2: To establish an in vivo proof of concept for SHAPE in swine melanoma 
using IFP measurements obtained with an invasive, intra-compartmental pressure monitor 
as the reference standard. 
4 
Hypothesis 2: A significant (p ≤ 0.05) inverse linear relationship between IFP and 
subharmonic amplitude with an |r|-value above 0.75 can be obtained in vivo in a swine 
model. 
 
Specific aim 3: To implement a subharmonic algorithm on a Sonix RP US scanner to 
enable acoustic output optimization, subharmonic amplitude detection and display in real 
time and calibrate for in vivo SHAPE using athymic, nude, female rats. The rats will be 
implanted with human breast cancer cells and SHAPE measurements compared to IFP 
measurements obtained with an invasive, intra-compartmental pressure monitor as the 
reference standard.  
Hypothesis 3: A significant (p ≤ 0.05) inverse linear relationship between IFP and 
subharmonic amplitude with an |r|-value above 0.75 can be obtained in vivo in a rat 
model. 
 
Specific aim 4: To evaluate the ability of SHAPE to track changes in IFP by studying 
human breast cancer xenografts in athymic, nude, female rats before and after 
administration of a chemotherapy agent (paclitaxel) and comparing results to intra-
compartmental pressure measurements.  
Hypothesis 4: The changes in tumor IFP (anticipating lowered by 6.9 to 4.4 mmHg) 
induced by the chemotherapy agent paclitaxel  can be monitored using SHAPE. 
5 
2 BACKGROUND AND LITERATURE REVIEW 
2.1 Breast Cancer  
 Breast cancer accounts for 29% of new cases of non-cutaneous cancer and 15% of 
all cancer related deaths in women in the US second only to lung cancer. In 2015 it is 
estimated that 231,840 new cases will be diagnosed and 40.290 deaths will occur [17]. 
Breast cancer can also be found in men and children but it is a small subgroup consisting 
of less than 1% of breast cancer cases and deaths [17]. Breast cancer is normally 
diagnosed with mammography, US, breast MRI or biopsy and treated with a combination 
of chemotherapy, radiation therapy, endocrine therapy and surgery depending on the 
severity of the disease and the patient's age, gender and menopausal status [18]. 
Anatomical TNM (tumor, node, metastases) staging of breast cancer is classified by 
tumor size, lymph node status and whether or not the cancer has metastasized to other 
parts of the body. Stage 0 is essentially carcinoma in situ, for stage 1 the tumor is smaller 
than 20 mm with possible lymph node involvement but no metastases. At stage 2 the 
cancer has not metastasized to distant tissue and the tumors can be (1) larger than 50 mm 
but there is no lymph node involvement or (2) smaller than 50 mm but the cancer has 
spread to lymph nodes below the collarbone [19]. 
2.1.1 Locally Advanced Breast Cancer  
  In the United States, close to 5 - 20 % of newly diagnosed breast cancer and 10 - 
30% of all primary breast cancer is diagnosed as LABC and the numbers are even higher 
in underdeveloped areas of the world [3, 4]. A patient is diagnosed with LABC when the 
cancer has reached a TNM stage of 3 or 4. To be considered a cancer in TNM stage 3 the 
patient must fulfill one or more of these criteria: 1) the tumor is larger than 5 cm across, 
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2) inflammatory breast cancer has developed, 3) underarm lymph nodes are metastatic or 
4) other lymph nodes in the vicinity of the breast are metastatic [3, 4]. TNM stage 4 
lesions have metastasized to parts of the body other than the breast [3].  
2.1.2  Treatment for Locally Advanced Breast Cancer 
 Neoadjuvant chemotherapy (systemic preoperative chemotherapy) is currently the 
standard of care for LABC [5, 6]. It is administrated before the primary surgical treatment 
and usually followed with surgery and radiation. Currently, a combination of taxanebased 
(e.g. paclitaxel or docetaxel) and anthracyclinebased (e.g. doxorubicin) therapy is 
recommended as studies suggest a higher response rates when the drugs are combined 
rather than given in isolation [20, 21]. When compared with adjuvant chemotherapy 
(postoperative therapy), neoadjuvant chemotherapy yields similar results for both overall 
survival (OS) (69 % neoadjuvant, 70 % adjuvant, p = 0.8) and disease-free survival 
(DFS) (53 % adjuvant, 55 % neoadjuvant, p = 0.5) [7]. These findings were further 
supported by a meta-analysis of 3,946 patients that showed no statistical difference 
between neoadjuvant and adjuvant chemotherapy in OS and disease progression [8]. 
Thus, the postponement of surgery does not affect the outcome of the treatment [9, 10]. 
Neoadjuvant chemotherapy can however, offer considerable benefits to the patient by 
shrinking the tumor and even in some cases offer complete pathologic response [5, 8, 9]. 
This in turn increases the possibility of breast conservation as breast conservation surgery 
is only performed for tumors that are less than or equal to 4 cm in diameter [5, 8-10]. 
Furthermore, if mastectomy is inevitable systemic preoperative therapy makes it possible 
to reconstruct the breast immediately as opposed to waiting for two years as is the case 
without systemic preoperative therapy [9]. This proves invaluable as it is of great 
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personal importance for the self-esteem and quality of living of the patient to be able to 
conserve as much as possible of the remaining breast tissue [9]. Another potential 
advantage is the possible reduction in local recurrence rate [6]. Neoadjuvant 
chemotherapy can also offer an early indication of a patient’s response to chemotherapy, 
thereby distinguishing responders and non-responders and allowing for further 
personalization of treatment. Consequently, monitoring breast cancer response to 
neoadjuvant therapy provides the possibility of adjusting the treatment if the patient is 
responding poorly or not at all, resulting in substantial advantages for the patient [5, 9]  
2.1.3 Neoadjuvant Chemotherapy Monitoring  
 Currently, pathology is considered the gold standard for predicting residual tumor 
following neoadjuvant chemotherapy although clinical examination, mammography, 
magnetic resonance imaging (MRI) and US are also commonly used [18]. In a study 
conducted by Yeh et al. these four techniques were compared to pathology to determine 
their relative accuracy. MRI showed a 71 % agreement rate providing the results closest 
to pathology, while US showed a 35 % agreement rate, mammography 26 % and clinical 
examination 19% respectively. However, MRI had some serious complications as it over- 
or underestimated the amount of residual cancer in 29 % of patients [18]. A study using 
scintimammography with [
99m
Tc]-sestamibi showed that both DFS (p < 0.01) and OS (p 
= 0.01) is lower for patients with high uptake of [
99m
Tc]-sestamibi after neoadjuvant 
chemotherapy [22]. A small study (18 patients) using color and power Doppler US 
assessed the response to therapy by monitoring the vascularity of the tumors [23]. No 
change in tumor vascularity indicated a lack of response to treatment whereas a decrease 
in the tumor vascularity indicated a good response. Furthermore, power Doppler US has 
8 
been used to assess the vascularity index (VI) for breast cancer tumors (VI = number of 
colored pixels within tumor volume/number of pixels within tumor volume) [24]. Thirty 
patients were scanned every 1-2 weeks while undergoing neoadjuvant chemotherapy (9-
12 weeks in total). There were two predictors for a good response; all patients with a VI 
increment above 5 % showed good response and for patients with a peak VI above 10 % 
there was a 94.1 % response rate. The increased response in hypervascular tumors is 
believed to be due to better access of the chemotherapy agent to the tumor through the 
vasculature [24].  
2.2  Interstitial Fluid Pressure  
 One of the indicators that have been suggested for monitoring neoadjuvant 
chemotherapy is the IFP [11]. Generally, IFP is 10 to 30 mmHg higher in cancerous 
tissue than in normal tissue, although values up to 107 mmHg have been recorded in 
melanoma [11, 12]. This increase is attributed to leaky and collapsed vessels, fibrosis, 
high cell density and a defective lymphatic system in the tumor [12, 13, 25]. Due to the 
abnormal vasculature, tumor microvascular pressure (MVP) has been shown to be equal 
to IFP [26, 27]. Currently, IFP can only be measured with an invasive wick-in-needle or 
micropuncture techniques [12]. IFP studies using the wick-in-needle technique have been 
conducted in cancers of the breast, cervix, head, neck, skin, lymph nodes and others [11, 
13, 28-30]. Moreover, high IFP in tumors may lead to reduced drug delivery to the tumor 
and, therefore, it has been suggested that using IFP lowering drugs can further improve 
the outcome of neoadjuvant chemotherapy [30]. 
 Taghian et al. [2] used a wick-in-needle technique to monitor the IFP of breast 
cancer before and after neoadjuvant chemotherapy with two drugs used consecutively. 
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When used as a first drug, paclitaxel decreased the IFP by 36 % (p = 0.02) whereas with 
doxorubicin as the first drug there was only an 8 % reduction (p = 0.41). As this was a 
hypothesis-generating study they did not present any outcome related to the relationship 
between IFP and therapy response [2]. However, the level of IFP has been shown to 
predict DFS for cervical cancer (34 % DFS if IFP > 19 mmHg, 68% DFS if IFP < 19 
mmHg; p = 0.002) [28]. Thus, the level of IFP in tumors could potentially be used to 
monitor the response to neoadjuvant chemotherapy and offer early adjustment of therapy 
for non-responders. Moreover, Less and colleagues [13] have suggested that IFP could be 
helpful for localization of tumors as there is a sharp drop in IFP in the tumor periphery. 
Therefore, a noninvasive method for monitoring IFP offers great benefits for cancer 
therapy as it would make it easier to monitor neoadjuvant treatment response throughout 
the chemotherapy cycles, to customize patient treatment and possibly even to localize 
tumor margins [13]. 
2.3 Ultrasound  
 US is defined as sound at frequencies greater than the upper limit of human 
hearing. In 1942, Dr. Karl Dussik was the first to suggest that US could be utilized to 
visualize brain tumors [31, 32], paving the way for the imaging of other anatomical 
structures within the human body and since then the field of medical US has grown to 
become the second most common imaging modality after x-ray [33]. The popularity of 
US as an imaging modality can be attributed to a number of factors; US is based on non-
ionizing radiation, it is portable and low cost as well as offering real time imaging [33]. 
 US imaging is based on the reflection of sound waves from different tissue 
structures. An US transducer converts electrical signals into mechanical pressure wave 
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that transmits a sound wave into the body that is either reflected, transmitted or absorbed 
depending on the characteristics of the tissue [33]. The average speed of sound in tissue 
is: 
 𝒄𝒕𝒊𝒔𝒔𝒖𝒆 = 𝟏𝟓𝟒𝟎 𝒎/𝒔 (2.1) 
and differs only by a few percent for most soft tissues but for bone it is almost 
double[34]. 
 The acoustic impedance Z [Rayl]: 
 𝒁 = 𝝆𝒄 (2.2) 
where ρ is the density [kg/m3] and c the speed of sound in the medium [m/s], can be used 
to characterize the acoustic properties of tissues and determine the reflection at the 
boundary of two different tissues [33]. In a pulse echo setup the transducer receives the 
portion of the wave reflected back from the boundary of tissue 1 and tissue 2 which can 
be described by the reflection factor R using the acoustic impedances of the two tissues: 
 𝑹 =  
𝒁𝟐−𝒁𝟏
𝒁𝟐+𝒁𝟏
 (2.3) 
The portion of the wave that continues through can be described with the transmission 
factor T: 
 𝑻 = 𝟏 + 𝑹 (2.4) 
The acoustic impedance for different types of tissues vary a great deal (table 2.1 [34]) and 
therefore enable the successful imaging of different tissues [35].  
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Table 2.1 Acoustic impedance of different tissue types in the human body 
 
Tissue Z [MRayls] 
Blood 1060 
Bone 1990 
Brain 1035 
Breast 1020 
Fat 928 
Heart 1060 
Kidney 1050 
Liver 1050 
Muscle 1041 
Table 2.1 Acoustic impedance (Z) of different tissue types in the human body. The differences in Z enable 
the successful imaging of different tissue [34]. 
 
 
 
2.4 Contrast Agents  
 The use of UCAs was first suggested by Gramiak and Shah in 1968 [36]. 
Vascular contrast agents are gas-filled microbubbles (diameter less than 8 µm) that 
improve the depiction of vascularity in small vessels and deep tissue in US images by 
enhancing the difference in reflectivity between tissue and the agent [14]. The contrast 
agents are either injected as a bolus or infused and due to their small size, these 
microbubbles can traverse the entire capillary bed [14]. The reflectivity of blood is 30 to 
60 dB weaker than backscatter from the surrounding tissue which makes depiction of 
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vessels difficult without the aid of contrast [37]. As an approximation to clarify this we 
consider the reflection factor for the boundary of air and water. The characteristic 
acoustic impedance of air at 1 atm and 20°C is [38]: 
 𝒁𝒂𝒊𝒓 = 𝟒𝟏𝟓𝑹 (2.5) 
whereas for fresh water at 20°C it is [38]: 
 𝒁𝒘𝒂𝒕𝒆𝒓 = 𝟏. 𝟒𝟖 ∙ 𝟏𝟎
𝟔𝑹 (2.6) 
which is four orders of magnitude larger than Zair. When calculating the reflection factor 
for water and air it is apparent that almost all of the energy is reflected as R = 1 denotes 
complete reflection: 
 𝑹 =  
𝟏.𝟒𝟖∙𝟏𝟎𝟔−𝟒𝟏𝟓
𝟏.𝟒𝟖∙𝟏𝟎𝟔+𝟒𝟏𝟓
= 𝟎. 𝟗𝟗𝟗 (2.7) 
Therefore, due to the great difference in acoustic impedance between the microbubbles 
and the tissue the backscatter is enhanced [39]. 
2.4.1 Availability and Safety of Ultrasound Contrast Agents 
 Currently, only three UCAs are approved by the Food and Drug Administration 
(FDA) for human clinical in the United States; Definity (Lantheus, N Billerica, MA), 
Optison (GE Healthcare, Princeton, NJ) and very recently Lumason (previously 
SonoVue; Bracco Diagnostics Inc., Monroe Township, NJ) [40]. However, a number of 
other UCAs available and they are listed in table 2.1. 
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Table 2.2 Available UCAs 
Agent Shell Gas Mean 
diameter 
(μm) 
Resonance 
frequency 
(MHz) 
FDA 
approved 
Sonazoid Lipid Perfluorobutane 2.4-3.5 
(median) 
4.4   
Definity Lipid Perfluropropane 1.1-3.3 2.7  Cardiac 
Levovist Galactose/ 
palmitic 
acid 
Air 2.0-4.0 2.0   
Lumason Lipid Sulfurhexafluoride 1.5-2.5 3.1 Cardiac 
Optison Albumin Octafluoropropane 2.0-4.5 2.0  Cardiac 
ZFX Lipid Perfluoropentane 2.1-4.0 3.0   
Table 2.1. Properties of available UCAs.  
 
 
 
 In October 2007, a black box warning was issued for Definity and Optison by the 
FDA after 11 deaths and 190 “severe cardiopulmonary reactions” occurring after contrast 
injection [41-43]. The deaths were in an at-risk patient population and not verifiably 
related to the UCA. The black box warning has since been modified to be less restrictive 
but nonetheless this was a setback to the field. A retrospective multicenter analysis of 
42,408 patients showed no significant difference in death rates between patients receiving 
contrast and those that did not [41]. Moreover, Main et al.[42] showed in another 
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retrospective study that patients receiving Definity were 24% less likely to die within a 
day from contrast injection than those that did not receive contrast, suggesting that UCAs 
are safe to use even in at risk populations[43]. Table 2.2 lists the risk of death or serious 
complications from different procedures, putting the safety of UCAs into perspective 
[43]. Note that the risk ratio for contrast administration is assuming that all reported 
events are in direct relation to the UCAs and thus in reality the probability is likely much 
lower. 
 
 
 
Table 2.3 Comparison of risk for UCAs and different procedures 
Procedure Risk 
Contrast administration 1:500,000 
Diagnostic coronary angiography 1:1,000 
Exercise treadmill testing 1:2,500 
Table 2.3 Risk of death or serious complications from different procedures [43] 
 
 
 
2.4.2 Modeling of Ultrasound Contrast Agents  
 When contrast agents are subjected to a great enough pressure field (> 200 kPa) 
nonlinear response is generated as bubble contraction is limited due to the compression of 
gas. This nonlinearity can be described by models of oscillation of gas bubbles. Lord 
Rayleigh (1917) first solved the equations for bubble dynamics and after several 
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modifications over the course of a century the Rayleigh Plesset equation can be used to 
describe bubble oscillations. Here R is the dynamic radius of the bubble with time and 
terms containing the derivatives ?̈?and ?̇?are nonlinear [39]. 
 𝑹?̈? +
𝟑𝑹?̇?
𝟐
=
𝟏
𝝆
((𝒑𝟎 +
𝟐𝝈
𝑹𝟎
− 𝒑𝒗) (
𝑹𝟎
𝑹
)
𝟑𝜿
+ 𝒑𝒗 − 𝒑𝟎 −
𝟐𝝈
𝑹
−
𝟒𝜼?̇?
𝑹
+ 𝑷(𝒕)) (2.8) 
R0 is the radius of the bubble at equilibrium, ρ is the liquid density, p0 is the hydrostatic 
pressure in an incompressible fluid surrounding the bubble pv is the liquid vapor pressure, 
κ is the polytropic gas index, σ is the surface tension, η shear viscosity of the fluid and 
P(t) is the pressure field acting on the bubble. 
2.4.3 Imaging Modes using UCAs 
 Contrast agents are used with various imaging methods, the most common of 
which are listed here. 
Fundamental B Mode Imaging 
 This imaging mode is essentially conventional B mode imaging with 
microbubbles resulting in an enhanced signal from the contrast agent when compared to 
tissue. However, in most cases such as when imaging the myocardium this method 
suffers from a low contrast to tissue ratio. 
Harmonic B Mode Imaging 
 At higher acoustic outputs UCAs act as nonlinear oscillators producing 
harmonics, ultra- and subharmonics in the received signals. In harmonic imaging the 
backscatter is received at twice the transmit frequency (2f0). The harmonic signal from 
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the bubble is much stronger than that from the tissue leading to enhanced contrast to 
tissue ratio when compared to imaging at the fundamental. 
Harmonic Power Doppler Imaging 
 Harmonic Power Doppler imaging is similar to conventional Power Doppler 
except the signal is received at twice the transmit frequency (second harmonic) making 
the imaging of small vessels easier.  
Subharmonic Imaging 
 In SHI pulses are transmitted at a frequency f0 and the echoes are received at half 
that frequency (f0/2). SHI has been shown to be a feasible option for contrast enhanced 
breast imaging due to marked subharmonic generation by UCAs relative to limited 
subharmonic generation in tissues [44]. 
Pulse Inversion Imaging 
 In pulse inversion imaging two pulses, one in phase the other 180° out of phase, 
are transmitted in succession and the received echo is summed up, cancelling out any 
linear component from the tissue and odd harmonic components fn where n = 2m+1; (m = 
0, 1, 2... ), resulting in a strong signal at even harmonic components from the UCAs. 
Power Modulation Imaging 
 Pulses with two different amplitudes, normally a and 0.5a, are transmitted and the 
received signal adjusted and subtracted to remove linear signals from the tissue leading to 
a better contrast to tissue ratio. 
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2.5 Microbubbles as Pressure Monitors 
 The idea of using microbubbles to monitor pressure was first suggested by 
Fairbank and Scully [45]. Given the difference in compressibility between the 
surrounding medium and a microbubble any changes in hydrostatic pressure induce 
changes in the size of the microbubble [1]. This in turn affects the reflectivity and 
resonant frequency of the microbubble [1, 15]. The methods studied to date for pressure 
measurements with microbubbles include (1) utilizing changes in resonant frequency of 
the microbubbles [15, 45], (2) employing the disappearance time of the microbubbles 
[46, 47] and (3) using the pulse echo amplitude of a single bubble [48]. However, these 
methods have not been tested in vivo due to lack of accuracy (errors > 10 mmHg) 
observed under ideal in vitro conditions. 
 To date this has been an area of interest to researchers as the use of microbubbles 
in conjunction with US would be a non-invasive and safe way of measuring pressure. The 
methods studied can be divided into four categories: 
1) Pressure measurements utilizing changes in resonant frequency 
The relationship between changes in the surrounding pressure and resonant frequency of 
the microbubble can be described by: 
 𝐟𝟎 =
𝟏
𝐝𝛑
(
𝟑𝐤𝐩
𝛒
)
𝟏
𝟐⁄
 (2.9) 
Where f0 is the resonant frequency, d is the diameter and k is the specific heat ratio of gas 
in the microbubble, p is the pressure and ρ is the density of the surrounding medium [49]. 
This relationship was first employed by Fairbank and Scully to monitor pressure in the 
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heart [45]. They were able to simulate cardiac pressure measurements and measure a shift 
in resonance frequency. However, they had some difficulty with experimental setup and 
uniformity of the bubbles (20 - 40 µm in diameter) leading to broad range in resonance 
frequency that influenced the measurements so that the proposed resonance shift was not 
seen [45]. Pressure measurements employing the disappearance time of the microbubbles 
Using sonic cracking Bouakaz et al. demonstrated a relationship between the 
disappearance time and pressure with a sensitivity of 50 mmHg. Contrast agents in vitro 
were exposed to an ultrasound burst and the disappearance time measured [46]. This 
method was then refined by Postema et al. that used the subharmonic response instead of 
the fundamental and were thus able to measure pressure changes of 11 mmHg [47]. 
2) Pressure measurements using the pulse echo amplitude of a single bubble 
Hök suggested that by measuring the echo amplitude of a single microbubble it would be 
possible to estimate the hydrostatic pressure of the surrounding medium. Theoretical 
modeling and in vitro experiments provided a proof of concept. Nevertheless, this method 
had an error of 24 mmHg and thus needed considerable improvement before it could 
become a clinical option [48]. 
3) Subharmonic-aided pressure estimation (SHAPE)  
As this technique is an integral part of this study it will be reviewed in detail in a 
subsequent chapter.  
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2.6 Subharmonic Aided Pressure Estimation  
 Our group developed a novel technique, SHAPE, utilizing the subharmonic 
amplitude of the scattered signal from the microbubbles for pressure tracking [1]. Using 
the UCA Levovist (Schering AG, Berlin, Germany) and a pulse-echo setup with single-
element transducers in a water-tank, it was demonstrated that the relationship between  
 
 
 
 
 
 
subharmonic amplitude and acoustic output can be described by a characteristic 
sigmoidal curve (figure 2.1 [1]) with three different stages of subharmonic generation 
Figure 2.1 Characteristic sigmoidal curve as demonstrated by Shi et al. Three stages were observed 
occurrence (0 - 0.3 MPa), growth (0.3 - 0.6 MPa) and saturation (0.6 - 1.2 MPa) [1]. 
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depending on the acoustic output: i.e., occurrence, growth and saturation. The occurrence 
and saturation stages are not favorable for pressure estimation as the subharmonic 
response to hydrostatic pressure changes is weak in these stages [1]. This is likely due to 
limited subharmonic generation in the occurrence phase and noise from bubble 
destruction in the saturation phase. However, in the growth stage there is an inverse linear 
relationship (9.6 dB decrease in subharmonic amplitude over 0 to 186 mmHg, r = 0.98, p 
< 0.05) between the hydrostatic pressure and the subharmonic amplitude that can be used 
as a scale to estimate the hydrostatic pressure [1]. This inverse linear relationship has also 
been confirmed for other UCAs and over different frequencies (2.5 – 6.6 MHz) and 
acoustic outputs (0.35 - 0.60 MPa) showing a decrease of 10-14 dB over a pressure range 
of 0 to 186 mmHg for different UCAs (r
2
 > 0.97, p < 0.05) [50].  
 Furthermore, our group has also looked at a variety of pressure estimation 
applications. An in vivo proof of concept for cardiac SHAPE was established by 
measuring the aortic pressure of two dogs (using two single element transducers to 
implement SHAPE) [51]. As that setup is not clinically acceptable, a Sonix RP scanner 
(Analogic Ultrasound, Richmond, BC, Canada) was modified for SHAPE and initial 
studies in canines showed that left ventricular pressures could be estimated in vivo with 
errors as low as 0.19 mmHg [52]. Moreover, a Logiq 9 scanner (GE Healthcare, 
Milwaukee, WI) was modified for portal vein pressure estimation  in canines (n = 14). 
These studies confirmed that there is an inverse linear relationship (r
2
 > 0.90; p ≤ 0.01) 
between the subharmonic amplitude and portal vein pressures [53].  
 Several other groups have reported a relationship between subharmonic amplitude 
and hydrostatic pressure, using both single-element transducers and commercial US 
21 
scanners in vitro [54-56]. One group studied the response of the subharmonic, 
fundamental and second harmonic amplitudes to changes in hydrostatic pressure with the 
UCA Optison (GE Healthcare, Princeton, NJ). They showed that an increase in 
hydrostatic pressure leads to a time-dependent decrease in subharmonic amplitude (r > 
0.71) [54-56]. Andersen and Jensen [57] investigated the ratio between the energy of the 
subharmonic and the fundamental amplitudes to estimate pressure using the UCA 
SonoVue (Bracco, Milano, Italy) and showed that there was an inverse linear relationship 
between this ratio and hydrostatic pressure with linear correlation coefficients ranging 
from 0.89 to 0.98 depending on acoustic driving pressure (range: 485 - 500 ). Frinking 
and colleagues [58] have shown, using an experimental phospholipid shell agent, that 
depending on the acoustic output level the subharmonic amplitude either decreases with 
increasing hydrostatic pressure as displayed by our group and others, or increases with 
hydrostatic pressure. As an example, at 50 kPa an increase of 18.9 dB in the subharmonic 
amplitude was seen over a 40 mmHg increase in hydrostatic pressure but at 400 kPa a 
decrease of 9.6 dB was seen over 185 mmHg. However, they used an experimental agent 
and our setup has not been able to distinguish a subharmonic response from noise at 
acoustic outputs lower than 100 kPa using commercial agents [50]. Faez et al. observed 
both an increase and a decrease in the subharmonic amplitude with increasing hydrostatic 
pressure using BR14 microbubbles (Bracco Research S.A., Geneva, Switzerland). They 
reported a maximum of 8 dB increase in subharmonic amplitude over 15 kPa 
(corresponding to 113 mmHg) when transmitting at 10 MHz and 240 kPa acoustic output 
[59]. Potentially, these discrepancies are due to differences in experimental setup or the 
properties of the UCAs used. 
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3 MATERIALS AND METHODS 
3.1 Materials  
3.1.1 Isotonic Diluent  
 Isotonic diluent was purchased from Val Tech Diagnostics (Pittsburgh, PA). 
3.1.2 Definity 
 Definity was supplied by Lantheus Medical Imaging (North Billerica, MA). 
Definity is a lipid shelled, perflutren gas based microbubble with a mean diameter of 1.1 
- 3.3 µm and a resonance frequency of 2.7 MHz. It was selected for this study for three 
main reasons: 1) it is commercially available in the United States, 2) it is approved by the 
FDA for echocardiography use in the United States and finally 3) our previous in vitro 
studies on lower frequency (< 7 MHz) SHAPE in a water-tank showed up to 13 dB 
decrease (r
2
 = 0.98, p < 0.05) in subharmonic amplitude for Definity at 6.6 MHz transmit 
frequency when increasing the hydrostatic pressure from 0 to 186 mmHg, thereby giving 
promise for higher frequencies [50]. Definity comes in a 2 ml glass vial and needs to be 
activated before use according to manufacturer's instructions. Before activation Definity 
is a clear liquid at room temperature. The agent is activated in a VIALMIX unit 
(Lantheus Medical Imaging, North Billerica, MA) for 45 seconds and is milky white once 
activated. Definity should be used within 5 minutes of activation but can be reconstituted 
for up to 12 hours by gently shaking the vial. 
3.1.3 Cells and Culture Material 
 A human breast adenocarcinoma cell line MDA - MB - 231 was used as a breast 
cancer model. MDA - MB - 231 tumors have been shown to be sensitive to to paclitaxel 
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treatment (see specific aim 4) as both CDK1 activity is increased and volume reduced in 
MDA - MB - 231 breast cancer xenografts, both parameters indicating treatment response 
[60]. The cells were supplied as a gift by Dr. Susan Lanza-Jacoby's laboratory at Thomas 
Jefferson University (Philadelphia, PA).  
 Cell culture materials; PBS Dulbeccos phosphate-buffered salt solution (PBS) 
(1X; Without calcium and magnesium); Trypsin cell culture dissociation reagent, (1X , 
0.05% Trypsin without calcium, magnesium, or sodium bicarbonate); Dulbecco's 
Modification of Eagle Medium (DMEM) (1X with L-Glutamine, 4.5g/L Glucose and 
without Sodium Pyruvate); research grade fetal bovine serum (FBS) and Penicillin 
Streptomycin solution (100X, 10,000 IU Penicillin, 10,000ug/mL Streptomycin) were 
purchased from Fisher Scientific (Waltham, MA). 
3.1.4 Matrigel 
 In order to ensure the maximum possible number of tumors and to promote 
growth, the MDA-MB-231 cells were implanted together with growth factor reduced 
(GFR) Matrigel basement membrane matrix, that was purchased from BD Biosciences 
(San Jose, CA). Matrigel is a product of overproduction of a variety of growth 
stimulatory tumor matrix proteins from a rat sarcoma that produces a biologically active 
matrix once injected into the rats thereby facilitating tumor attachment [61]. Moreover, in 
a study by Mullen et al. the take rate of MDA - MB - 231 cells in mice was increased 
from 50% without Matrigel to 100% with Matrigel [62, 63].  
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3.1.5 Paclitaxel 
 The chemotherapy agent paclitaxel (30 g per 5 ml) was manufactured by Sagent 
Pharmaceuticals (Schaumburg, IL) and purchased from BDI Pharma (Columbia, SC). 
paclitaxel was selected for the treatment phase of the study as it was shown to lower IFP 
in a study in 54 patients with LABC, which measured IFP before and after treatment with 
one of two chemotherapy agents, and found that paclitaxel therapy significantly 
decreased the mean IFP (by 36%; p=0.02) whereas the other agent did not. A bolus dose 
of 5 mg/g was selected as it is the maximum paclitaxel dose tolerated by rats and higher 
doses e.g. 20 mg/g as is used in humans and mice, result in death [63]. 
3.1.6 Sonix RP Ultrasound Scanner and Linear Arrays 
 A commercial US scanner, Sonix RP (Analogic Ultrasound, Richmond, BC, 
Canada; Software version 3.2.2) was selected for this study as the Sonix RP system offers 
complete access to the radiofrequency (RF) data and offers a high degree of 
customization in the research mode on the scanner enabling the implementation of pulse 
inversion and customized solutions. Two different probes were used for this study. For 
the in vitro and in vivo proof of concept feasibility studies a high frequency linear array 
probe L14-5 (bandwidth 5 - 14 MHz, center frequency 7.5 MHz) was used, as the wide 
range in bandwidth allowed for a more thorough investigation of the effect of frequency 
on SHAPE. For the in vivo calibration and treatment phases a high frequency linear array 
probe L9-4 (bandwidth 4 - 9 MHz, center frequency 5 MHz)was selected based on the 
results of the feasibility and to ensure adequate reception of the subharmonic amplitude at 
subharmonic frequencies of 3.35, 4 and 5 MHz. 
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3.2 Methods  
3.2.1 In Vitro Parameter Optimization 
 Two different sets of experiments were conducted in vitro using a Sonix RP 
(Analogic Ultrasound, Richmond, BC, Canada) scanner and a high frequency linear array 
probe L14-5 (Analogic Ultrasound, Richmond, BC, Canada); a) the acoustic output levels 
were varied from 0.24 to 2.05 MPa peak to peak (full range of Sonix RP scanner;  
 
 
 
Figure 3.1 Water tank and acoustic setup with the L14-5 transducer. Notice the digital pressure gauge 
on the top of the tank and the syringe to alter the hydrostatic pressure. 
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measured with a 0.2 mm needle hydrophone (Sensitivity: 49.4 mV/MPa at 6.7 MHz and 
47.4 mV/MPa at 10 MHz; Precision Acoustics, Dorchester, Dorset, UK)) and the 
hydrostatic pressure held constant at 0 mmHg to establish the optimal acoustic output 
levels for pressure estimation (in the growth zone of the characteristic sigmoidal curve 
explained in section 2.6) and b) the hydrostatic pressure was varied from 0 to 50 mmHg 
(corresponding to the range of IFPs encountered in breast cancers) at the optimal power 
levels selected from the previous experiments [64, 65].  
3.2.1.1 Equipment Setup 
 An acrylic water-tank (inner dimensions: 11.75 cm x 8.25 cm x 8.25 cm) that can 
withstand pressures up to 100 mmHg was custom-built and used to investigate SHAPE at 
the IFP levels encountered in breast tumors (Figure 3.1). The tank was lined with 25.5 
mm of Sorbothane (McMaster-Carr, Atlanta, GA) to eliminate effects from standing 
waves and gum rubber of thickness 9.5 mm (McMaster-Carr, Atlanta, GA) was used to 
couple the Sorbothane to the isotonic diluent used for the experiments. A digital pressure 
gauge (OMEGA Engineering, Stamford, CT) was used to monitor pressure values inside 
the tank. The Sonix RP scanner was operated in the research mode with the L14-5 probe 
positioned at a 45° angle to an acoustically transparent window in the tank. The water-
tank was filled with isotonic diluent (800 ml, 25°C) and immersed in a larger water-bath 
also filled with isotonic diluent in order to provide easy coupling for the linear array to 
the pressurized tank. The contrast agent Definity was selected for this study as it is 
commercially available, approved by the FDA for echocardiography use in the United 
States and has been shown to react to pressure changes [50]. The agent was activated 
according to manufacturer's instructions and injected through an inlet on the tank (dose: 
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0.2 ml/l) and kept in suspension using a magnetic stirrer. To ensure an even concentration 
of agent within the tank, 30 s of mixing were allowed before starting measurements. Two 
transmission frequencies, 6.7 MHz and 10 MHz (subharmonic signal received at 3.35 and 
5 MHz, respectively) were considered. These transmit frequencies were selected as they 
fall within the frequency band of the US unit and can be used for clinical imaging of the 
breast as ultimately the goal is to employ SHAPE for human breast cancer IFP 
estimation. Pulse inversion was implemented on the scanner i.e. two consecutive pulses 
were transmitted 180° out of phase, the received signal summed up, and thus any linear 
components from the tissue were cancelled, thereby clarifying nonlinear signals from the 
bubbles. Each measurement was taken with the scanning depth fixed at 6 cm (frame rate 
9 Hz) and the focus at 4.25 cm (positioned approximately 1.5 cm within the water-tank; 
Figure 3.2). 
3.2.1.2 Acoustic Output Optimization 
 In order to establish the optimal acoustic output setting for pressure 
measurements, the hydrostatic pressure was kept at 0 mmHg and the acoustic output 
varied with a step size of 2 dB from -20 dB to 0 dB, equivalent to 0.24 to 2.05 MPa peak 
to peak, measured with a 0.2 mm needle hydrophone (Precision Acoustics, Dorchester, 
Dorset, UK). The subharmonic signals were plotted as a function of acoustic output. The 
acoustic output levels within the growth zone of the characteristic sigmoidal curve were 
then selected for further SHAPE investigations with varying hydrostatic pressure. 
3.2.1.3 Hydrostatic Pressure Variation 
 The hydrostatic pressure within the tank was varied from 0 to 50 mmHg (in steps 
of 10 mmHg, n = 3) by pumping air with a 100 ml syringe through a one-way valve 
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attached to an inlet on the tank (Figure 3.1). Pressure values were then compared using 
linear regression to the subharmonic amplitude extracted from the radio frequency (RF) 
data acquired with the Sonix RP scanner. 
3.2.1.4 Data Processing 
The RF data were extracted using programs obtained from Analogic Ultrasound 
and processed offline on a PC computer using Matlab (version R2011, Mathworks, 
Natick, MA) programs developed by our group. This processing method is a modification 
of the program utilized by Dave et al. [66]. A region-of-interest (ROI) of 4 mm by 4 mm 
was selected (see figure 3.2).  
The FFT of each vector within the ROI was computed and the subharmonic 
amplitude was then extracted from the spectra over a 1 MHz bandwidth (figure 3.3) 
around the subharmonic peak to minimize noise effects and the bandwidth selected based 
on previous work by our group at a 2.5 MHz transmit frequency (Dave 2012).  
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Figure 3.2 B-mode image of the water tank. The ROI used for SHAPE estimation is indicated by a red box 
and the focus depth of 4.25 cm with a red arrow. A clear difference can be seen between the UCA within 
the water tank and the isotonic diluent surrounding the tank. 
Figure 3.3 An example spectra where the subharmonic amplitude was extracted over a 1 
MHz bandwidth around the subharmonic peak to minimize noise effects. 
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 The subharmonic amplitude was then averaged over all the vectors in the ROI and 
in frames corresponding to 2 seconds to eliminate effects from noise. The Matlab code 
for this algorithm can be found in appendix A. Linear regression analysis was used to 
determine the relationship between the hydrostatic pressure and the subharmonic 
amplitude. All statistical analyses were conducted using Stata 9.0 (Stata Corporation, 
College Station, TX).  
3.2.2 In Vivo Proof of Concept in Swine 
 As an initial proof-of-concept, SHAPE was tested on five Sinclair swine with a 
weight of 9.5 ± 4.1 kg (Sinclair Bio Resources, Columbia, MO) with naturally occurring 
melanomas. Sinclair swine are commonly used as an animal model for study of human 
melanoma as the tumors they develop are similar to malignant melanomas in humans [67, 
68]. They have a very high incidence of melanoma and at 1 year of age 85% of Sinclair 
swine have developed tumors [67]. Moreover, a number of factors are similar between 
melanoma in the swine and humans such as histopathology and spontaneous development 
of tumors, making this an excellent model for tumor studies [67]. Furthermore, the 
tumors are cutaneous, allowing for easier scanning, and melanomas have been shown to 
have a raised IFP [69]. Therefore, Sinclair swine make an excellent proof of concept 
model for SHAPE. 
3.2.2.1 Animal Procedure 
 The animals were sedated with an intramuscular injection of 0.04 mg/kg of 
Atropine (Med-Pharmex Inc, Pomona, CA) and 5 mg/kg of Telazol 
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(Tiletamine/Zolezepam, Pfizer, New York, NY). General anesthesia was then maintained 
with 2-4% of Isoflurane (Iso-thesia; Abbott Laboratories, Chicago, IL) through an 
endotracheal tube during the procedure. Body temperature was kept steady with a heating 
pad and after the procedure the animals were euthanized with an intravenous injection of 
0.25 ml/kg of Beuthanasia. All experiments were supervised by the Laboratory Animal 
Services Department and conducted in agreement with a protocol approved by Thomas 
Jefferson University’s Institutional Animal Care and Use Committee. Appendix B 
contains the original procedure proposal for this in vivo proof of concept study. 
3.2.2.2 Contrast Injection and Tumor Scanning 
 As for the in vitro water-tank study, a Sonix RP US scanner with a high frequency 
linear array L14-5 was used to scan the melanomas and surrounding tissue. Pulse 
inversion was implemented and depth varied from 2.0 to 4.0 cm depending on tumor size 
and location (frame rate 12-13 Hz depending on depth). Two transmission frequencies 
6.7 MHz and 10 MHz were considered (subharmonic frequencies of 3.35 and 5 MHz, 
respectively). The optimal acoustic output setting for SHAPE could not be determined in 
vivo due to time constraints, but acoustic output levels of -4 dB, -8 dB and -12 dB were 
used as they showed the most promise in vitro. To ensure constant concentration of agent 
throughout the experiment, 3 ml of Definity were injected into a 50 ml saline bag and the 
agent-saline mix was then infused through an ear vein at a rate of 6.25 ml/min. The 
presence of Definity and contrast flow was confirmed by a radiologist before data 
acquisition. Both B-mode frames and RF data were acquired. A needle based pressure 
monitor system (Stryker, Berkshire, UK), often applied for the measurement of intra-
compartmental syndrome was used as a reference standard to measure IFP within the 
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tumors and 3 to 5 cm from the tumor periphery in the surrounding normal tissue (Figure 
3.4) [70, 71]. First, the pressure monitor is zeroed by pressing a button on the device. 
Care was taken so that the device was at the angle of insertion when zeroed to minimize 
measurement errors. Then the needle is inserted into the tissue, 1 ml of saline is injected 
into the tissue and then the monitor stabilizes at the IFP level of the tissue (stabilization 
time < 30 s). Pressure measurements were taken in triplicate (n = 3) with the intra-
compartmental Stryker pressure monitor both in normal tissue and in the melanoma (one 
after the other), while simultaneously acquiring the US RF data  
 
 
 
Figure 3.4 Stryker intracompartmental pressure monitor was used as a reference standard. 
 
 
 
3.2.2.3 Data Processing and Analysis 
RF data were processed offline using the same algorithms as in vitro with the ROI 
selected close to the tip of the pressure monitor needle. The location of the needle tip was 
verified by a radiologist with 12 years of experience (Figure 3.5). Linear regression  
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analysis was performed with Stata 9.0 (Stata Corporation, College Station, TX) to 
compare the subharmonic amplitude extracted from the RF data with the pressure values 
acquired with the Stryker pressure monitoring system. Tumor volume was estimated 
using the formula for an ellipsoid  volume of an ellipsoid [71]: 
 𝐕 =  
𝛑 
𝟔
∙ 𝐥 ∙  𝐰 ∙  𝐡 (3.1) 
where length (l), width (w) and height (h) were measured from B-mode images of the 
melanoma. 
Figure 3.5 An example B mode image from one of the swine melanomas. Tumor periphery is indicated by 
a blue dotted line and the location of the Stryker pressure monitor needle is indicated with a red circle as 
identified by a radiologist. 
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3.2.3 Calibration in Rats  
3.2.3.1 Modification of US Scanner 
 A thorough requirements analysis and specifications document was developed by 
our group for implementation on the Sonix RP based on the results of the in vitro water-
tank and in vivo proof of concept studies (see appendix C). The scanner was then 
modified by Analogic Ultrasound and LBJ Development (Fort Mitchell, KY) to enable 
subharmonic amplitude detection and display in real time for SHAPE. The design 
parameters selected based on the results of specific aims 1 and 2 are listed in table 3.1. 
 
 
 
Table 3.1 Design parameters for modified Sonix RP scanner 
Parameter Requirement 
Frequency settings 10/5 MHz, 8/4 MHz, 6.7/3.35 MHz  
Screen display Dual screen SHI and B mode 
Power optimization Automatic with graph 
Pulse inversion  Implemented 
Output file type  RF, BPR (B mode) 
Table 3.1. Design parameters implemented on the Sonix RP scanner in order to enable SHAPE and SHI. 
These parameters were selected based on the results of specific aims 1 and 2.  
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The ultimate goal of this project is to use SHAPE on locally advanced breast 
cancer in human patients and so the high frequency linear array probe L9-4/38 was 
selected for scanning, as its bandwidth (4 to 9 MHz; center frequency 5.5 MHz) is 
suitable both breast cancer imaging and for the proposed frequency range from the in 
vitro experiments and proof of concept, especially for the lower receive frequencies. An 
8.0 MHz transmit frequency and 4.0 MHz receive frequency were implemented on the 
Sonix RP system for pressure estimation as a compromise between the in vitro 
optimization in specific aim 1 and 2 and the frequency band of the transducer. Moreover, 
pulse inversion was implemented to minimize linear components of the signal. When 
imaging breast tumors with SHAPE it is essential that the sonographer has a good view 
of both the regular B mode imaging, to view tissue structures, and the subharmonic mode 
for visualizing tumor vessels. Therefore, the modified solution was designed with a dual 
screen display, with the B mode image on one side and the equivalent B mode image 
with a subharmonic region of interest (ROI) on the other side. This format is based on 
previous work by our group [72]. The size of the ROI can be set as appropriate, with the 
largest ROI covering the whole image.  
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Figure 3.6 Dual screen display showing a subharmonic ROI on the left and B mode imaging on the right. 
 
 
 
The dual screen display as well as the operating board for the modified software 
solution can be seen in figure 3.6. Moreover, a feature allowing for the optimization of 
acoustic output for SHAPE was added. A graph of the subharmonic amplitude vs. 
acoustic output was generated (Figure 3.7) and an acoustic output, corresponding to the 
growth stage and thereby strongest subharmonic response; was then selected by the 
radiologist or sonographer and used to acquire the pressure measurements. This is in part 
based on a solution previously proposed by our group [73]. 
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3.2.3.2 Cell Culture 
 MDA-MB-231 breast cancer cells were cultured in petri dishes with media (89 % 
DMEM, 10% serum, 1% Penicillin Streptomicin) and stored in an incubator (set at 37°C 
and 5.0% CO2). The cells were harvested for injection using the method detailed in 
appendix D, centrifuged (4°C, 10 minutes, 1000 rpm) and combined with a 
saline/Matrigel mixture (50 % saline and 50 % Matrigel) before injection. The Matrigel 
was prepared using the method detailed in appendix E. 
3.2.3.3 Injection of Cells into Mammary Fat Pad and Tumor Growth 
 Twenty one athymic, nude, female, rats (100-120 g, 6 weeks old at cell injection, 
NIHRNU-F, Taconic, Hudson, NY) were randomized into 3 groups of 7 animals, each 
group corresponding to 21, 24 or 28 days post tumor implantation. The NIHRNU rat 
model was selected as it has been shown to have a take rate of 67% with MDA-MB-231 
Figure 3.7 An example of the acoustic output curve generated by the modified solution. The green arrow 
points to the data point selected for scanning. Note the s shape of the curve corresponding to theory. 
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xenografts [74]. Moreover, it offers easy scanning as the rats are nude and only minimal 
shaving is required before scanning. Appendix F lists the preparation for cell injection. 
Subcutaneous injections were done with a 24 gauge TB needle and each rat was injected 
with 5  106 MDA - MB - 231 tumor cells in the mammary fat pad (cell count performed 
with a hemocytometer; a 0.5 ml tumor cell suspension with 50 % saline and 50 % 
Matrigel). The cells were administered to the rats in a laminar flow hood.  All rats were 
anesthetized using 2-4% Isoflurane (Iso-thesia; Abbott Laboratories, Chicago, IL); the 
anesthesia was induced in an anesthesia chamber and then maintained throughout the 
procedure with a mouthpiece. Throughout the experiment the rats were placed on a 
warming blanket to maintain body temperature After injections the animal was returned 
to the cage, given food and water ad libitum, monitored and maintained for a period of 
21, 24 or 28 days depending on the group. Tumor growth was inspected on day 7, 14, and 
21 and tumor dimensions measured with a caliper once tumors had formed. Animal 
procedures are detailed in appendix G. 
3.2.3.4 Tumor Scanning and Contrast Injection 
 Out of the 21 rats injected with MDA - MB - 231 tumor cells, 14 developed 
tumors (67% take rate) and were included in the calibration study. The rats were 
anesthetized using established methods (see 3.2.3.3.). Throughout the experiment the rats 
were placed on a warming blanket to maintain body temperature and finally a heating 
lamp was used to enlarge the tail vein for venous access. The rats received a bolus 
intravascular (IV) injection of the UCA Definity through a 24 gauge needle in the tail 
vein. Each dose of Definity was 180 μl/kg with a maximum total dose of 0.2 ml and each 
injection was followed with a 0.2 ml saline flush. First, SHI was performed with the 
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modified Sonix RP scanner and a high frequency linear array L9-4 at a transmit 
frequency 8 MHz and receiving at 4 MHz and the optimal acoustic output established 
using the customized software solution. Then, the IFP of the normal mammary fat pad (n 
= 3) as well as the tumor (n = 3) was measured with an intra-compartmental Stryker 
pressure monitor (selected as the reference standard technique for this study). The Stryker 
pressure monitor is an invasive needle based system for measuring the IFP (see 3.2.2.2.). 
Needle placement, contrast and ROI were verified by a radiologist with 12 years of 
experience. SHAPE data was collected for 2 s for each measurement at a scanning depth 
of 4 cm and a frame rate 15 Hz. Focus was dependent on tumor location. Concurrently 
with the IFP measurements, SHAPE measurements were taken (n = 3) at the optimal 
acoustic output setting and averaged for each SHAPE data point.  
3.2.3.5 Euthanasia 
 At the end of the study the rats were sacrificed with standard procedures by 
placing them in a standard CO2 chamber with a regulator. Cervical dislocation was 
performed after sacrificing the rats in the CO
2
 chamber.  
3.2.3.6 Data Processing and Analysis 
 Changes were made to the algorithm used for data processing relative to the in 
vitro and proof of concept studies mainly by introducing thresholding to eliminate noise 
from the tissue as even though pulse inversion was implemented some tissue signal was 
still present. The algorithm used for the processing of RF data from the calibration and 
treatment phases is in appendix H.  
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The RF data acquired was transferred to a PC computer and run offline through a Matlab 
program. There the fast Fourier transform (FFT) was taken for each vector in each frame 
and the values calculated in logarithmic form (i.e., in dB). A maximum projection image 
(MPI) was generated and from that image the user selected an ROI containing either 
tissue, vessel or tumor depending on the selection. For this ROI thresholding was 
performed by calculating the mean pixel value (MPV) for all frames combined (MPVall) 
and for each frame separately (MPVframe). For each frame, MPVframe was then 
compared to three different thresholds corresponding to 1.00x, 1.15x, 1.30x MVPall and 
an average taken for all pixel values above the threshold for that frame (corresponding to 
the subharmonic amplitude). The results for all the frames were then averaged over 2 s. 
The threshold values were selected based on previous work by our group [72]. 
 
 
 
Figure 3.8 Block diagram of the off-line processing performed on the RF data. 
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 The relationship between microbubble based subharmonic signals and the IFP 
results measured with the intra-compartmental monitor was established (essentially 
calibrated) using linear regression analysis. Moreover, linear regression analysis was 
conducted to investigate the relationship between IFP and tumor volume and generate 
calibration equations that were then applied to an independent data set from the treatment 
phase of the study. Analysis of variance (ANOVA) was used to compare the 3 different 
thresholds. All statistical analyses were conducted using Stata 9.0 (Stata Corporation, 
College Station, TX) and Matlab (version R2014b, Mathworks, Natick, MA). Tumor 
volume was estimated using the formula for an ellipsoid where length, width were 
measured with a caliper and height estimated from B-mode images of the tumor 
(equation 3.1). 
3.2.4 Treatment in Rats  
 Once the calibration phase was concluded, 64 nude rats with MDA-MB-231 
xenografts were scanned 21, 24 or 28 days from injection to test the ability of SHAPE to 
monitor changes in IFP before and after administration of the chemotherapy agent 
paclitaxel. Procedures were identical to the calibration phase in almost all respect and 
where they differ the changes are detailed below. 
3.2.4.1 Cell Culture 
 The same procedure as in the calibration phase (see section 3.2.3.2.) was used for 
cell culturing for the treatment phase. 
3.2.4.2 Injection of Cells into Mammary Fat Pad and Tumor Growth 
 The same method was followed as in the calibration phase (see section 3.2.3.3.). 
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3.2.4.3 Tumor Scanning, Contrast Injection and Paclitaxel Treatment 
 SHAPE data was collected at a transmit frequency 8 MHz and receiving at 4 MHz 
with the modified Sonix RP scanner and a high frequency linear array L9-4 for 2 s for 
each measurement at a scanning depth of 4 cm and a frame rate 15 Hz. Focus was 
dependent on tumor location. As before, all rats were anesthetized using established 
methods (see 3.2.3.3.) and placed on a warming blanket to maintain body temperature. 
The rats received a bolus IV injection (dose 180 μl/kg) of Definity through a 24 gauge 
needle in the tail vein. Each injection was followed with a 0.2 ml saline flush. SHAPE 
and the Stryker pressure monitor measurements were performed before and 48 hours after 
administration of a single IV injection in a lateral tail vein of 5 mg/kg of the 
chemotherapy agent paclitaxel (Mayne Pharma, Paramus, NJ) on day 21, 24 or 28 post 
tumor implantation. The paclitaxel dosage (5 mg/kg) was selected based on a study by 
Shord and Camp where a bolus dose of 5, 10 or 20 mg/kg was injected to Sprague 
Dawley rats. At 20 mg/kg which is equivalent to the therapy regimen in humans all the 
rats died within 2 hours of administration, at 10 mg/kg 56% of the rats died within 2 
hours and the remaining rats died within 24 hours. However, no morbidity was seen for 
the rats receiving 5 mg/kg and thus they concluded that to be the highest possible safe 
dose [63]. Additionally, tumor volumes were measured with a caliper every other day to 
allow growth curves to be established and compared. Each study lasted for no longer than 
1 hour. 
3.2.4.4 Euthanasia 
 Euthanasia was carried out as before (see section 3.2.3.5.). 
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3.2.4.5 Data Processing and Analysis 
 The same algorithm was used for the processing of the RF data as in the 
calibration phase (see section 3.2.3.6). The relationship between microbubble based 
subharmonic signals and the IFP results measured with the intra-compartmental monitor 
was established using linear regression analysis and compared to the calibration 
equations from specific aim 3. Moreover, linear regression analysis was conducted to 
investigate the relationship between IFP and tumor volume and ANOVA to compare the 
3 different thresholds. This analysis was then repeated with treatment (control/paclitaxel, 
pre/post treatment) and time (days) using linear regression, ANOVA and paired t-test as 
applicable to establish if any interactions occur. All statistical analyses were conducted 
using Stata 9.0 (Stata Corporation, College Station, TX) and Matlab (version R2014b, 
Mathworks, Natick, MA). Tumor volume was estimated using the formula for an 
ellipsoid where length, width were measured with a caliper and height estimated from B-
mode images of the tumor (equation 3.1). Linear regression analysis was used to evaluate 
the relationship between tumor volume and tumor IFP. 
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4 RESULTS AND DISCUSSION 
4.1 In Vitro Optimization 
 For clinical breast US imaging applications a minimum center frequency of 7 
MHz is required according to the American Institute of Ultrasound in Medicine 
guidelines for breast US [75]. Thus, before initiating in vivo studies of SHAPE in breast 
tumors the frequency (and acoustic output) needed to be optimized in vitro for the Sonix 
RP scanner and the contrast agent Definity as no in vitro data was available for 
frequencies higher than 6.6 MHz and only single element transducers had been used for 
frequencies lower than 6.6 MHz [50]. In order to optimize tumor SHAPE in vitro, 
experiments focusing on first, the acoustic output of the scanner (full range: -20 dB to 0 
dB) at transmit frequencies of 6.7 MHz and 10 MHz, and secondly, hydrostatic pressure 
variation over a pressure range simulating the IFP in human breast cancer tumors (0 to 50 
mmHg), were conducted. The results of these studies are presented in sections 4.1.1. and 
4.1.2. and finally conclusions of the in vitro studies are presented in section 4.1.3. The 
following results were published in Ultrasonics [76]. 
4.1.1 Acoustic Output Optimization 
 The full range of acoustic output on the Sonix RP scanner is designated from -20 
dB to 0 dB. Over this range, an approximate sigmoidal curve for the relationship between 
the subharmonic amplitude and the acoustic output showed the three stages of 
subharmonic generation: i.e., occurrence (-20 dB to -16 dB) where there was minimal 
change in the subharmonic amplitude as the subharmonic could not be distinguished from 
the noise floor; growth (-16 dB to - 4 dB) where there was a sharp rise in subharmonic 
amplitude and there is maximum sensitivity to pressure changes (Shi et al. 1999), and 
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finally saturation (-4 dB to 0 dB) where again the subharmonic levels off due to noise 
from bubble destruction and inertial cavitation (Figure 4.1). 
 
 
 
 
 
 
 Based on this relationship four acoustic output levels covering the growth stage 
and its boundaries were chosen for further investigation of hydrostatic pressure variation 
(figure 4.2.); -16, -12, -8 and -4 dB (corresponding to 0.33, 1,06, 1.33, 1.68 MPa and 
Figure 4.1  Subharmonic response to changes in acoustic power with the occurrence, growth 
and saturation phases. The relative subharmonic amplitude is scaled so that 0 dB refers to the 
lowest measured subharmonic amplitude and the remaining values are then scaled to that 
point as such: relative subharmonic amplitude = measured subharmonic amplitude – lowest 
measured subharmonic amplitude. The points corresponding to the acoustic output levels that 
were further investigated in the hydrostatic pressure variation component of this study are 
indicated with a blue circle. 
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0.24, 1.21, 1.52 and 1.78 MPa peak to peak for 6.7 MHz and 10 MHz transmission, 
respectively). These values were selected to provide the opportunity to investigate both 
the boundaries of the occurrence - growth phases (-16 dB) and the growth - saturation 
phases (-4 dB) as well as two different acoustic output levels within the growth phase (-8 
and -12 dB). No fundamental peak was observed in these data sets as it was cancelled out 
by the pulse inversion implemented. 
4.1.2  Hydrostatic Pressure Variation 
 In the water-tank an inverse linear relationship was seen over a pressure change 
from 0 to 50 mmHg at both 6.7 MHz and 10 MHz transmission frequencies and all 
acoustic output levels -16 dB to -4 dB (r
2
 ≥ 0.63; p < 0.05; Figure 4.2.).  
 
 
 
 
Figure 4.2 Maximum decrease in subharmonic signal amplitude for Definity as a function of frequency and 
acoustic output (n = 3) when hydrostatic pressures were varied from 0 to 50 mmHg. 
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The r
2
 values from the linear regression analysis were consistently higher for a 
transmission of 10 MHz (receiving the subharmonic at 5 MHz) than for 6.7 MHz 
(receiving the subharmonic at 3.35 MHz). Moreover, pressure measurements taken at -16 
dB (start of the growth phase) showed a limited sensitivity compared to the higher 
acoustic output settings likely due to a lack of subharmonic generation (still in the 
occurrence phase). The largest drop in subharmonic amplitude (corresponding to the 
maximum sensitivity for pressure estimation), 11.36 dB over 50 mmHg, was seen at 10 
MHz and -8 dB (r2 = 0.95; p < 0.01; Figure 4.3.).  
 
 
 
 
Figure 4.3 The largest drop in subharmonic amplitude of 11.36 dB over 50 mmHg, was seen at 10 MHz 
and -8 dB (r2 = 0.95; p < 0.01). 
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4.1.3 Discussion for In Vitro Optimization 
 An inverse linear relationship between changes in hydrostatic pressure and 
subharmonic amplitude (r
2
 as high as 0.95, p < 0.05) over the IFP pressure range found in 
tumors (0–50 mmHg) was confirmed in vitro. This study has established that for the 
contrast agent Definity and the acoustic parameters tested (transmission frequencies 6.7 
MHz and 10 MHz and acoustic output ranging from -20 dB to 0 dB), a transmission 
frequency of 10 MHz (receiving at 5 MHz) and acoustic power of -8 dB offer the greatest 
sensitivity for pressure estimation with SHAPE. Furthermore, correlation between IFP 
and subharmonic amplitude was generally lower when transmitting at 6.7 MHz and this 
setup may have been pushing the bandwidth limitations of the probe as the subharmonic 
received at 3.35 MHz is at the lower end of the probe’s bandwidth (5– 14 MHz). This is 
consistent with what has been reported previously by our group where a 13.3 dB drop in 
subharmonic amplitude was noted when the hydrostatic pressure in a water-tank was 
increased from 0 to 186 mmHg at a transmit frequency 6.6 MHz and an acoustic output 
of 0.35 MPa with a pulse echo setup using single element transducers (r
2
 = 0.9, p < 0.05) 
[50]. However, a decrease in subharmonic amplitude as high as 11.36 dB is surprisingly 
large given our previous measurements, but the difference can likely be explained by the 
difference in frequency. Moreover, higher acoustic output levels are seen in the growth 
zone for this in vitro calibration when compared to the previous studies by our group. 
One possible explanation is that two different water-tanks were used as a new one was 
built for this study to minimize standing waves and noise. Possibly, the acoustic window 
on the new tank may have introduced more attenuation than expected. Due to the design 
of the tank hydrophone measurements were not possible through the acoustic window. 
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Several other groups have reported a relationship between subharmonic amplitude and 
hydrostatic pressure, using both single element transducers and commercial US scanners 
in vitro [54-56]. One group studied the response of the subharmonic, fundamental and 
second harmonic signals to a change in hydrostatic pressure with the contrast agent 
Optison (GE Healthcare, Princeton, NJ). They showed that an increase in hydrostatic 
pressure leads to a time-dependent decrease in subharmonic amplitude (r > 0.71) [54-56]. 
Andersen and Jensen [57] investigated the ratio between the energy of the subharmonic 
and the fundamental amplitudes to estimate pressure using the contrast agent SonoVue 
(Bracco, Milan, Italy) and determined that there was an inverse linear relationship 
between this ratio and hydrostatic pressure changes; albeit with a high standard deviation. 
As no fundamental was present due to pulse inversion, this could not be tested with our 
data. Frinking and colleagues [58] have shown that depending on the acoustic power 
level the subharmonic amplitude either decreases with increasing hydrostatic pressure (as 
determined by our group and others), or increases with hydrostatic pressure. As an 
example, at 50 kPa an increase of 18.9 dB in the subharmonic amplitude was seen over a 
40 mmHg increase in hydrostatic pressure, but at 400 kPa a decrease of 9.6 dB was seen 
over 185 mmHg. However, they used an experimental phospholipid shell agent and our 
setup has not been able to distinguish a subharmonic response from noise at acoustic 
pressures lower than 100 kPa using commercial agents [50]. Faez et al. [59] observed 
both an increase and a decrease in the subharmonic amplitude with increasing hydrostatic 
pressure using BR14 microbubbles (Bracco Research S.A., Geneva, Switzerland). They 
reported a maximum of 8 dB increase in subharmonic amplitude over 15 kPa 
(corresponding to 113 mmHg) when transmitting at 10 MHz and 240 kPa acoustic output. 
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Potentially, these discrepancies are due to differences in experimental setup or the 
properties of the contrast agents used. Our group studied ambient pressures varying with 
time in a flow phantom using the contrast agent Sonazoid (GE Healthcare, Oslo, 
Norway), the Sonix RP (transmit frequency 2.5 MHz, acoustic output 0.22 MPa) and the 
same Matlab program as was used in this study (with modifications) with promising 
results, root mean square (RMS) error of 8.16 mmHg and absolute error of 6.70 mmHg 
[77]. However, no studies using a commercial scanner in the frequency range needed for 
breast US (center frequency at least 7 MHz) are available and consequently, this study 
adds the possibility of branching further into pressure measurements for breast tumors 
and other tumors that are superficial or located close to the surface (high frequency 
scanning). Moreover, the goal of achieving an r > 0.90 (specific aim 1) has been met and 
optimization of acoustic output and frequency using the Sonix RP scanner and contrast 
agent Definity has been established providing a sound basis to continue for in vivo 
studies. 
4.2 Proof of Concept in Swine Melanomas 
 The feasibility of SHAPE was tested on naturally occurring swine melanomas as a 
proof of concept before starting a calibration study in rats with breast cancer xenografts 
and to refine the requirements and design for the SHAPE software application 
implemented on the Sonix RP scanner. This work is presented in section 4.2.1. and 
discussed in section 4.2.2. The following results were published in Ultrasonics [76]. 
4.2.1 SHAPE Measurements Compared to IFP in Swine Melanomas 
 Table 4.1. lists the results of all the measurements taken in vivo for the proof of 
concept study. In all cases but one an inverse linear relationship was observed. In the case 
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where the subharmonic amplitude increased with higher IFP there was not a statistically 
significant relationship (Tumor 4, 10 MHz, 8 dB; p = 0.06) as α = 0.05 was set as the 
significance level. Only one melanoma showed statistically significant results for IFP at 
the transmission frequency of 6.7 MHz (at 8 dB acoustic power; 2.88 dB over 40 mmHg 
change, r
2
 = 0.91, p = 0.02), presumably due to the subharmonic frequency (3.35 MHz) 
lying at the lower end of the linear array’s bandwidth. 
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Table 4.1 Summary of in vivo proof of concept measurements 
Tumor 
(Swine) 
Frequency 
[MHz] 
Acoustic 
Output 
[dB] 
Subharmonic 
amplitude in 
tissue [dB] 
St. dev 
[dB] 
Subharmonic 
amplitude in 
tumor [dB] 
St. dev 
[dB] 
Change in 
subharmonic 
amplitude [dB] 
Tissue 
IFP 
[mmHg] 
Tumor 
IFP 
[mmHg] 
Change 
in IFP 
[mmHg] 
(r2, p) 
Slope 
[dB/mmHg] 
Intercept 
[dB] 
1(1) 
10 
-4 66.52 4.08 55.27 1.90 -11.26 1 17 16 0.82, 0.012 -0.70 67.23 
-8 66.90 2.22 57.19 1.69 -9.71 1 17 16 0.90, 0.004 -0.61 67.51 
6.7 
-4 67.45 2.75 60.31 7.03 -7.14 2 17 15 0.40, 0.177 -0.48 68.40 
-8 67.92 0.86 60.67 8.24 -7.25 2 17 15 0.37, 0.207 -0.48 68.89 
2(2) 10 
-4 67.87 2.17 60.52 0.67 -7.35 8 61 53 0.89, 0.005 -0.14 68.98 
-8 70.18 0.90 56.90 2.01 -13.28 8 61 53 0.97, 0.001 -0.25 72.19 
4(4) 10 
-8 35.94 0.57 39.21 1.09 3.27 20 69 33 0.64, 0.056 0.07 34.61 
-12 36.13 0.93 35.53 4.19 -0.60 18 71 32 0.17, 0.425 -0.01 36.33 
5(3) 
10 
-8 44.56 1.13 37.84 1.27 -6.72 7 40 30 0.92, 0.003 -0.20 45.98 
-12 42.50 2.27 38.89 0.37 -3.61 8 40 0 0.63, 0.058 -0.11 43.40 
6.7 
-8 49.36 0.87 46.48 0.42 -2.88 10 40 0 0.91, 0.003 -0.10 50.31 
-12 43.94 2.24 43.79 2.89 -0.15 10 40 0 0.10, 0.542 -0.01 43.99 
Table 4.1. A summary of in vivo measurements showing SHAPE results compared to the pressure monitor. One animal was eliminated due to technical 
difficulties with the pressure monitor and not all conditions were considered for all animals due to time constraints. Note that tumor numbers are not consistent 
with swine numbers (shown in parentheses). 
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 However, for 10 MHz transmission frequency the relationship between the 
subharmonic amplitude and the IFP was more linear (r
2
 ≥ 0.67; p < 0.05) for all animals. 
Data from one swine were eliminated, due to technical difficulties with the Stryker 
pressure monitor. For the remaining swine the IFP was always lower than 11 mmHg in 
normal tissue and in the melanomas IFP was higher than 16 mmHg, as expected from the 
literature (Figure 4.4) [11, 13, 28-30].  No significant relationship was observed between 
tumor volume and tumor IFP (r
2 
= 0.08, p=0.07; figure 4.5.). Due to time limitations 
imposed by the agent infusion (< 8 minutes) not all frequency/acoustic output settings 
were considered for each swine. An infusion was employed to minimize any timing 
effects in UCA concentration and no trend as a function of time was seen in the signals. 
The subharmonic signals were steady during the in vivo measurements (average standard  
deviation 0.39 dB; range: 0.25 – 0.69 dB).  
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Our analysis indicates that there is a statistically significant difference (p < 0.01) in 
slopes and offsets between tumors and for the offset depending on power level (p = 0.05). 
However, there is not a significant difference in slopes with power level (p = 0.16) and no 
significant difference between the slopes and offsets and frequency (p < 0.71).  
 An inverse linear relationship between hydrostatic pressure and subharmonic 
amplitude (r
2
 = 0.63 – 0.95, p < 0.05) was confirmed in vivo and the best acoustic 
parameters for SHAPE using Definity in this parameter space were determined to be at 
10 MHz and acoustic output settings of -4 or -8 dB (Figure 4.4.). 
 
 
Figure 4.4 Best fit in vivo measurements showing SHAPE results compared to the pressure 
monitor for 10 MHz. The difference between tissue and tumor IFP is clearly captured by SHAPE. 
Note that for a clearer comparison of best fit results, relative values for subharmonic amplitude (0 
dB corresponding to the lowest dB value and then subharmonic amplitude difference relative to 
that value is reported) are used in the figure whereas actual values are used in Table 4.1. 
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4.2.2 Discussion for In Vivo Proof of Concept in Swine Melanomas 
 In vivo proof-of-concept for SHAPE as a noninvasive monitor of IFP has been 
provided in four swine with naturally occurring melanoma and the results strongly 
indicate the feasibility of using SHAPE as a noninvasive pressure monitor of IFP in 
tumors. In vivo, the IFP was always lower than 11 mmHg in normal tissue and in the 
melanomas IFP was higher than 16 mmHg, as expected from the literature [11, 13, 28-
30]. SHAPE showed excellent correlation with IFP values obtained in normal tissues and 
in the tumor using the Stryker needle-based pressure measurements (r
2
 = 0.67 – 0.96, p < 
0.01) with optimal sensitivity at a transmission frequency of 10 MHz and acoustic output 
settings -4 or -8 dB. These acoustic output levels are high compared to other in vivo 
studies but could be explained by higher frequency settings or difference in equipment 
Figure 4.5 No significant relationship was found between tumor volume and tumor pressure 
(r
2
 = 0.08, p = 0.07). 
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setup [52, 53, 66, 78]. This is further supported by a study by, Faez et al. where they 
looked at subharmonics in chicken embryos at 4-7 MHz and did not see any subharmonic 
generation below 300 kPa, which was a higher threshold than expected from their in vitro 
studies. 
 The main limitation of this study is the small sample size in vivo (only four 
swine). Nonetheless, this still constitutes as a proof of concept for SHAPE for estimating 
tumor pressure. Furthermore, correlation between IFP and subharmonic amplitude was 
generally lower when transmitting at 6.7 MHz and this setup may have been outside the 
bandwidth limitations of the probe as the subharmonic received at 3.35 MHz is at the 
lower end of the probe's bandwidth (5 - 14 MHz). Thus, a different linear probe will be 
considered for future studies (L9-4, frequency range 4 to 9 MHz). Additionally, only one 
location within each melanoma was considered. However, studies show that normally 
tumor pressure is homogenous in the tumor itself, but rapidly drops in its periphery so 
this should not affect the SHAPE measurements [13, 30]. Taghian et al. used a wick-in-
needle technique to monitor the IFP of breast cancer before and after neoadjuvant 
chemotherapy with two drugs used consecutively [2]. When used as a first drug, 
paclitaxel decreased the IFP by 36% (p = 0.02) whereas with doxorubicin as the first drug 
there was only an 8% reduction (p = 0.41). As this was a hypothesis-generating study 
they did not show any outcome related to the relationship between IFP and therapy 
response [2]. However, the level of IFP has been shown to predict DFS for cervical 
cancer (34% DFS if IFP >19 mmHg, 68% DFS if IFP <19 mmHg; p = 0.002) [28]. 
Boucher and Jain concluded that the wick in needle technique can be used for IFP 
measurements in human melanomas [69]. Thus, the level of IFP in tumors could 
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potentially be used to monitor the response to neoadjuvant chemotherapy and offer early 
adjustment of therapy for non-responders. Moreover, Less and colleagues have suggested 
that IFP could be helpful for localization of tumors as there is a sharp drop in IFP at the 
tumor periphery [13].  
 This is the first study of in vivo pressure estimation with contrast agents in 
tumors, but several studies looking at other in vivo applications have been conducted. 
Most notably, studies by our group have shown the SHAPE method to be feasible in low 
frequency application such as monitoring of cardiac and hepatic pressures in canines [52, 
53, 66]. Due to attenuation and differences between animals there may not be a general 
relationship between IFP and the subharmonic amplitude. However, from the in vitro 
study it is clear that an inverse linear relationship can be arrived at and the slopes and 
offsets give an indication that this holds true even with individual differences between 
animals. In clinical practice a calibration method implemented alongside the IFP pressure 
estimation may be beneficial. As this is a proof of concept study no such method was 
employed for this study. We are currently exploring what method can be used for 
calibration in IFP measurements. The subharmonic signal in vivo did not vary greatly 
with time (maximum standard deviation 0.69 dB). This suggests that SHAPE is 
independent of the concentration within the ROI, as was also shown by Shi et al.[1]. 
Results from this study demonstrate that SHAPE may be useful for the noninvasive 
monitoring of IFP. Furthermore, a significant (p ≤ 0.05) inverse linear relationship 
between IFP and subharmonic amplitude with an r-value above 0.75 was obtained 
thereby fulfilling the requirements of specific aim 2. If proven viable, SHAPE has the 
potential to provide benefits for cancer therapy as it is noninvasive and thus, there is less 
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risk and more comfort for the patient than with the wick-and-needle method. Moreover, it 
would make it easier to customize individual patient treatment if SHAPE were found to 
be able to monitor neoadjuvant treatment response throughout the chemotherapy cycles. 
4.3 Calibration in a Murine Model 
 Calibration is necessary for estimating absolute pressure values in vivo. However, 
differences between individuals could be too great for an overall calibration value to be a 
viable option. Thus, it has been suggested that estimating the relative change in pressure 
should be sufficient to monitor treatment. In order to investigate if there is a universal 
relationship between IFP and subharmonic amplitude that could be applied in vivo, 
calibration experiments were implemented in a rat model. From the calibration a set of 
equations were developed and applied to an independent data set. Moreover, we also 
investigated if the changes in subharmonic amplitude accurately represent the change in 
IFP. This work is presented in sections 4.3.1. through 4.3.4. and discussed in section 
4.3.5. 
4.3.1 Calibration Equations 
 Of the 25 rats implanted with MDA-MB-231 for the initial calibration studies, 16 
(64%) exhibited tumor growth and 13 (52%) were successfully imaged. A maximum 
intensity projection SHI grayscale image from one of the tumors can be seen in figure 4.6 
a) with white arrows pointing out the vasculature. Figure 4.6. b) shows the same tumor in 
a MPI image with a different color scheme used for processing. An ROI (blue box in 
figure 4.6. b)was selected from that image and thresholds (100%, 115%, 130%) applied. 
The thresholding can be seen in figure 4.6. c), d) and e) for thresholds 100%, 115% and 
130% respectively. Notice how at the 100% threshold there is still some tissue signal 
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remaining whereas at the 130% threshold some of the vasculature is not included. Thus, 
for future studies a middle ground is suggested and at least not exceeding the 130% 
threshold. 
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Figure 4.6 Breast tumor xenograft (arrows) depicted in maximum projection intensity (MIP) SHI mode (a) 
and the same tumor using a different color scheme for clarity (b). The ROI selected from image (b) is then 
shown for 100% (c), 115% (d) and 130% (e) thresholds. Note the difference in noise and microvasculature 
depending on the threshold level. 
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 An inverse linear relationship was confirmed for all thresholds (r: -0.60 to -0.69, p 
< 0.01) with the highest correlation at the 115% threshold, correlation coefficient -0.64 or 
-0.69, depending on whether points where the standard deviation for IFP was higher than 
5 mmHg were included or not, respectively. Calibration equations derived from the linear 
regression models are listed in table 4.2. (SHA = Subharmonic amplitude). As the Stryker 
pressure monitor is sensitive to movement and the angle of insertion while measuring, a 
linear regression analysis was also performed after removing three data points where the 
standard deviation was larger than 5 mmHg, and where the ratio of standard deviation to 
the mean (standard deviation/mean) of three data points was larger than 50% and where it 
was larger than 100% (see appendix I). This is justifiable, as IFP is a static parameter not 
a dynamic one and therefore it can be concluded that changes in IFP where the standard 
deviation is larger than 5 mmHg are highly unlikely in a clinical setting and can be 
presumed to be a measurement error. Removing these data points resulted in a higher 
correlation in all cases although the difference was not statistically significant (p > 0.52) 
(table 4.2). For the analysis we used the actual values rather than relative values as they 
might skew the data when applying the equations to an independent dataset. Furthermore, 
for a clearer comparison of the results, relative values for subharmonic amplitude are also 
reported where 0 dB corresponds to the lowest dB value and the subharmonic amplitude 
value is relative to the difference to that value. Correlation is highest for 115% and lower 
for both 100% and 130%. This might indicate that the 115% thresholds provides the most 
accurate representation of the vessels in the tumor and tissue, since for the 100% 
threshold too much noise could still be present and for 130% it is possible that the signal 
from smaller vessels is getting lost due to the thresholding. 
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Table 4.2 Calibration equations derived from linear regression analysis 
Threshold IFP standard deviation 
> 5 mmHg included 
[mmHg] 
(r, p, n) IFP standard deviation 
> 5 mmHg not included 
[mmHg] 
(r, p, n) 
100% 
𝐼𝐹𝑃 =  
𝑆𝐻𝐴 − 117.49
−0.7297
 
r = -0.61, 
p < 0.01 
n = 28 
𝐼𝐹𝑃 =  
𝑆𝐻𝐴 − 117.64
−0.8548
 
r = -0.64,  
p < 0.01,  
n = 25 
115% 
𝐼𝐹𝑃 =  
𝑆𝐻𝐴 − 126.81
−0.825
 
r = -0.60, 
p < 0.01, 
n = 28 
𝐼𝐹𝑃 =  
𝑆𝐻𝐴 − 127.221
−1.0624
 
r = -0.69,  
p < 0.01, 
 n = 25 
130% 
𝐼𝐹𝑃 =  
𝑆𝐻𝐴 − 143.68
−0.8312
 
r = -0.58, 
p < 0.01, 
n = 28 
𝐼𝐹𝑃 =  
𝑆𝐻𝐴 − 143.89
−0.9923
 
r = -0.61, 
p < 0.01, 
n = 25 
Table 4.2. Calibration equations derived from linear regression analysis at all three thresholds investigated 
for this study. Results for both the case using all data points and the case eliminating data points where the 
standard deviation for IFP was larger than 5 mmHg are reported. For the analysis we used the actual values 
rather than relative values, they might skew the data when applying the equations to an independent 
dataset. IFP stands for interstitial fluid pressure and SHA stands for subharmonic amplitude.  
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 For the 100% threshold value the following equation was derived from linear 
regression analysis.  
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟏𝟕.𝟒𝟗
−𝟎.𝟕𝟐𝟗𝟕
 (4.1) 
This relationship is depicted with original values in figure 4.7 and relative values (0 dB 
corresponding to the lowest dB value and then subharmonic amplitude difference relative 
to that value is reported) in figure 4.8 for a clearer comparison. An inverse linear 
relationship was observed with a correlation coefficient r = -0.61, (p < 0.01, n = 28, 
figure 4.7 and 4.8). As can be seen in figure 4.7, the IFP standard deviation for some of 
the data points is covering close to 30% of the whole range of IFP measured. After 
removing the three data points where the standard deviation was higher than 5 mmHg, 
the following calibration equation was derived: Analysis after removing data points with 
standard deviation/mean > 50% or 100% can be found in appendix I 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟏𝟕.𝟔𝟒
−𝟎.𝟖𝟓𝟒𝟖
 (4.2) 
This results in a slightly higher correlation of r = -0.64 (p < 0.01, n = 25, figures 4.9. and 
4.10.) and suggests that by using a more precise hydrostatic pressure monitor the 
calibration could potentially be improved. The difference in slopes (p = 0.87) and 
intercepts (p = 0.16) before and after removing the data points were not significant. As 
before, one graph shows the inverse linear relationship with original values (figure 4.9) 
and the other shows the same relationship after making the subharmonic amplitude 
relative to the lowest dB value (figure 4.10). 
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Figure 4.7 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. 
 
 
 
 
Figure 4.8 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. Note that 
for a clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB 
value and then subharmonic amplitude difference relative to that value is reported). 
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Figure 4.9 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. 
 
 
 
 
Figure 4.10 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. Note that for a 
clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB value 
and then subharmonic amplitude difference relative to that value is reported). 
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For the 115% threshold the following equation was derived by linear regression analysis:  
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟐𝟔.𝟖𝟏
−𝟎.𝟖𝟐𝟓
 (4.3) 
Showing an inverse linear relationship with a correlation of r = -0.60 (p < 0.01, n = 28, 
figure 4.11.). As for the 100% threshold a relative value plot is also provided for clarity 
(figure 4.12.).  
 The calibration equation derived from the data set after removing points where 
IFP standard deviation is higher than 5 mmHg has a similar offset (p = 0.94) and (p = 
0.17): 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟐𝟕.𝟐𝟐𝟏
−𝟏.𝟎𝟔𝟐𝟒
 (4.4) 
By removing the three points the correlation goes up to r = -0.69 (p < 0.01, n = 25). 
Analysis where points where the standard deviation/mean > 50% or 100% can be found 
in appendix I This relationship can be seen in figures 4.13. and 4.14 for original and 
relative subharmonic values, respectively.  
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Figure 4.11 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold.  
 
 
 
 
Figure 4.12 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. Note 
that for a clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest 
dB value and then subharmonic amplitude difference relative to that value is reported). 
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Figure 4.13 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. 
 
 
 
 
Figure 4.14 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. Note that for a 
clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB value 
and then subharmonic amplitude difference relative to that value is reported). 
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 For the 130% threshold the following equation was derived from linear regression 
analysis: 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟒𝟑.𝟔𝟖
−𝟎.𝟖𝟑𝟏𝟐
 (4.5) 
Indicating an inverse linear relationship with r = -0.58 (p < 0.01, n = 28) as seen in figure 
4.15. The same plot with subharmonic amplitude values relative to the lowest 
subharmonic amplitude can be seen in figure 4.16. After removing points where IFP 
standard deviation was higher than 5 mmHg the following equation was derived:  
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟒𝟑.𝟖𝟗
−𝟎.𝟗𝟗𝟐𝟑
 (4.6) 
With a correlation coefficient r = -0.61 (p < 0.01, n = 25) as seen in figure 4.17 with 
original values and figure 4.18 with relative values. The difference in slopes (p = 0.65) 
and intercepts (p = 0.96) were not significant. 
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Figure 4.15 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. 
 
 
 
 
Figure 4.16 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. Note 
that for a clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest 
dB value and then subharmonic amplitude difference relative to that value) is reported. 
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Figure 4.17 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. 
 
 
 
 
Figure 4.18 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this 
case data points with IFP standard deviation larger than 5 mmHg have been eliminated. Note that for a 
clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB value 
and then subharmonic amplitude difference relative to that value) is reported. 
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 The three threshold groups are all significantly different from each other (p < 
0.01) and the difference between each group (100% and 115%, 100% and 130%, 115% 
and 130%) is also statistically significant (p < 0.01 in all cases). A box plot of the 
subharmonic data per threshold is shown in figure 4.19 and a plot of the comparison 
interval for all three thresholds in figure 4.20. The mean for subharmonic amplitude for 
thresholds 100%, 115% and 130% was 111.20 ± 10.59 dB, 119.70 ± 12.06 dB and 136.51 
± 12.77 dB, respectively. 
 
 
 
 
Figure 4.19 Box plot of the subharmonic data per threshold level All groups are significantly different 
from each other. 
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Figure 4.20 Graph showing the means for all three thresholds and how none of their comparison intervals 
overlap thereby showing that they are all significantly different. 
 
 
 
4.3.2 Verification of Calibration with an Independent Data Set 
 An independent dataset from the treatment phase of this study was used to test 
whether the calibration equations could be used to accurately estimate the pressure 
differential between the tumor and surrounding tissue. Using the subharmonic amplitude 
from the treatment phase and the calibration equations, a calculated IFP value was 
estimated and then compared to the measured IFP from the treatment phase. The results 
of this comparison can be seen in table 4.3. The correlation coefficient ranged from 0.71 
74 
to 0.73 and errors ranged from 7.80 mmHg to 8.55 mmHg. This is consistent with errors 
seen in vitro for SHAPE [77]. Moreover, a paired t-test showed that the measured and 
calculated groups were not significantly different (p > 0.14). The relationship between 
measured and calculated IFP is shown in figures 4.21, 4.22., and 4.23 for 100%, 115% 
and 130% thresholds respectively. 
 To better simulate a clinical setting all values with calculated IFP below -10 
mmHg were removed (9, 13, 13 points removed for 100%, 115% and 130% respectively) 
which resulted in a slightly higher correlation for all three thresholds (figures 4.24., 4.25. 
and 4.26. respectively) albeit the difference in correlation was not statistically significant 
(p > 0.66). Moreover, when removing the data points the measured and calculated IFP for 
100% and 130% thresholds were now significantly different (p = 0.01 for both groups) 
whereas the for 115% threshold the groups were the same (p = 0.14 to p = 0.90). This 
further indicates that the 100% and 130% thresholds are less suitable than the 115% 
threshold for this application. One possible explanation could be that there is still too 
much noise when using the 100% threshold and that for the 130% threshold the 
thresholding could be removing too much of the signal. The slopes and intercepts before 
and after removing data points where the standard deviation for IFP was larger than 5 
mmHg were not significant for any of the thresholds (p > 0.72). 
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Table 4.3 Comparison of measured and calculated IFP values 
Threshold r value, p 
value 
Absolute Error 
[mmHg] 
RMS error 
[mmHg] 
p value from t 
test 
n 
100% r = 0.72,  
p < 0.01 
8.55 10.34 0.19 104 
100%* r = 0.73, 
p < 0.01 
8.00 9.42 0.01 95 
115% r = 0.73,  
p < 0.01 
7.80 9.56 0.14 104 
115%* r = 0.74,  
p < 0.01 
6.24 7.49 0.91 91 
130% r = 0.71,  
p < 0.05 
8.71 10.78 0.30 104 
130%* r = 0.73,  
p < 0.01 
7.75 9.20 0.01 91 
Table 4.3. Results from applying calibration equations to an independent set of SHAPE data from the 
treatment phase of this study. Results for both the case using all data points and the case eliminating data 
points where the calculated IFP value was below -10 mmHg (denoted with a star shape * and gray shading 
for clarification) as IFP values that low are not clinically probable. For all three thresholds correlation was 
higher and errors were lower after eliminating these data points. RMS stands for root mean square. 
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Figure 4.21 Comparison for the 100% threshold of calculated IFP from calibration equations and SHAPE 
data from the treatment phase of the study and the corresponding IFP measured during data acquisition. 
 
 
 
 
Figure 4.22 Comparison for the 115% threshold of calculated IFP from calibration equations and SHAPE 
data from the treatment phase of the study and the corresponding IFP measured during data acquisition. 
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Figure 4.23 Comparison for the 130% threshold of calculated IFP from calibration equations and SHAPE 
data from the treatment phase of the study and the corresponding IFP measured during data acquisition. 
 
 
 
 
Figure 4.24 Comparison for the 100% threshold of calculated IFP from calibration equations where values 
below -10 mmHg have been removed and SHAPE data from the treatment phase of the study and the 
corresponding IFP measured during data acquisition. 
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Figure 4.25 Comparison for the 115% threshold of calculated IFP from calibration equations where values 
below -10 mmHg have been removed and SHAPE data from the treatment phase of the study and the 
corresponding IFP measured during data acquisition. 
 
 
 
 
Figure 4.26 Comparison for the 130% threshold of calculated IFP from calibration equations where values 
below -10 mmHg have been removed and SHAPE data from the treatment phase of the study and the 
corresponding IFP measured during data acquisition. 
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4.3.3 Differences in Subharmonic Amplitude Compared to Differences in IFP 
 The average difference between tumor IFP and tissue IFP was 13.26 ± 6.70 
mmHg and the average difference in subharmonic amplitude between tumor and tissue 
was -13.40 ± 5.25 dB (100%), -14.45 ± 5.59 dB (115%) and -15.47 ± 6.71 dB (130%). 
When comparing the change in subharmonic amplitude between tumor and tissue and the 
change in IFP between tumor and tissue for the calibration rats (n = 13, values averaged 
over three measurements) with linear regression analysis no significant relationship (p = 
0.71, 0.48, 0.37 for thresholds 100%, 115% and 130%, figures 4.27, 4.28 and 4.29, 
respectively) is seen and any correlation is positive as opposed to the statistically 
significant inverse linear relationship seen when looking at the tumor and tissue values 
together. This indicates that the variability in the IFP measurements is unacceptably high 
and that when using this equipment setup (Stryker pressure monitor, Sonix RP scanner 
and contrast agent Definity) the method is not sensitive enough for the low value pressure 
changes (IFP difference between tumor ranges from: 3.3 – 25.8 mmHg) seen in the rat 
tumors. However, as shown in section 4.3.1 the inverse linear relationship holds and the 
calibration with an independent dataset is also valid (section 4.3.3). This indicates that a 
calibration curve could potentially be a viable option. Further studies using a higher 
resolution scanner with better tissue suppression are needed. 
80 
Figure 4.27 The difference between the subharmonic amplitude in the tumor and tissue respectively are 
compared to the difference in IFP in the tumor and tissue respectively as measured by the pressure monitor 
at a 100% threshold. Note that no significant relationship was reported and the slope of the graph is 
positive. This suggests that at the 100% threshold using the Sonix RP scanner with the parameter space 
described in section 3.2.3  the SHAPE method is not sensitive enough for treatment monitoring. 
 
 
 
 
Figure 4.28 The difference between the subharmonic amplitude in the tumor and tissue respectively are 
compared to the difference in IFP in the tumor and tissue respectively as measured by the pressure monitor 
at a 115% threshold. Note that no significant relationship was reported and the slope of the graph is 
positive. This suggests that at the 115% threshold using the Sonix RP scanner with the parameter space 
described in section 3.2.3 the SHAPE method is not sensitive enough for treatment monitoring. 
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Figure 4.29 The difference between the subharmonic amplitude in the tumor and tissue respectively are 
compared to the difference in IFP in the tumor and tissue respectively as measured by the pressure monitor 
at a 130% threshold. Note that no significant relationship was reported and the slope of the graph is 
positive. This suggests that at the 130% threshold using the Sonix RP scanner with the parameter space 
described in section 3.2.3 the SHAPE method is not sensitive enough for treatment monitoring. 
 
 
 
4.3.4 Relationship between IFP and Tumor Volume 
 There was no significant linear relationship between IFP and tumor volume (r = 
0.49, p = 0.09, n = 13, figure 4.30.), as was also seen for the proof of concept study (cf. 
figure 4.5) [76]. 
y = 0.2699x - 19.051 
r = 0.27, p = 0.37, n = 13 
-25
-20
-15
-10
-5
0
0 5 10 15 20 25 30
D
if
fe
re
n
ce
 in
 S
u
b
h
ar
m
o
n
ic
 A
m
p
lit
u
d
e
 
(T
u
m
o
r 
- 
Ti
ss
u
e
) 
[d
B
] 
Difference in Interstitial Fluid Pressure (Tumor - Tissue) [mmHg] 
130% 
82 
 
Figure 4.30 No significant relationship was found between tumor volume and tumor pressure. 
 
 
 
4.3.5 Discussion for Calibration in a Murine Model 
 A new software application specifically designed for SHAPE was successfully 
implemented on a Sonix RP scanner and calibrated for the contrast agent Definity in a rat 
model with breast cancer xenografts. An inverse linear relationship between tumor IFP 
and subharmonic amplitude was observed in vivo in a rat model with human breast cancer 
xenografts. This is consistent with our results in the previous phases of this study 
(sections 4.1 and 4.2.) and other work by our group [1, 50, 52, 53, 66, 73]. The highest 
correlation (r = -0.69, p < 0.01, n = 25) was achieved at a 115% threshold after 
eliminating data points where the standard deviation for IFP was higher than 5 mmHg 
whereas the lowest correlation was achieved at a 130% threshold using all data points. 
Using the 115% threshold consistently resulted in higher correlation values than when 
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using the 100% and 130% threshold indicating that 115% is the optimal threshold value. 
From this linear regression analysis we obtained calibration equations that were then 
applied to an independent data set from the treatment phase of the study (section 4.4) to 
generate calculated IFP values that were then compared to the measured IFP values from 
the treatment data set. The measured and calculated IFP values did not differ for the 
115% threshold. However, for the 100% and 130% thresholds there was significant 
difference after removing data points that were not clinically possible and thus, those 
thresholds are likely allowing too much noise in the analysis (100%) and removing too 
much of the SHAPE data (130%) resulting in an inaccuracy in the calibration. Absolute 
errors ranged from 7.80 mmHg to 8.55 mmHg and root mean square errors ranged from 
7.49 mmHg to 10.78 mmHg, which is on par with previous work by our group in a flow 
phantom where absolute errors and RMS errors were 6.70 mmHg and 8.16 mmHg 
respectively [77].  
 Looking at the difference in tumor and tissue IFP and comparing that to the 
difference in tumor and tissue subharmonic amplitude showed no significant relationship 
(p-values ranging from 0.37 to 0.71; depending on threshold). This is discouraging as in 
the clinical setting it might not be possible to calibrate the IFP due to patient variability. 
The most likely explanation is that the error is too high to pick up the effect of the 
pressure change on this scanner. The transfer function of the scanner (section 3.2.3.1.) 
might be the culprit as microvessels are not always clearly visualized due to insufficient 
tissue suppression. Further studies are underway using a Logiq 9 (GE Medical Systems, 
Milwaukee, WI, USA) scanner in a human clinical trial building on the calibration from 
this study.  
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 No relationship was found between tumor IFP and tumor volume as was also the 
case in the proof of concept study [50]. This is not wholly unexpected as although some 
studies suggest correlation between tumor IFP and tumor volume others show none. For 
instance, Nathanson and Nelson [79] showed a strong relationship between tumor IFP 
and tumor size (r
2
 = 0.40; p = 0.021) in 25 patients with invasive breast cancer and others 
have reported a similar relationship for head and neck tumors [29] and metastatic 
melanomas [69]. However, for cervical cancer this is not the case and no relationship was 
found between tumor IFP and size [28, 80].  
 The current gold standard in IFP measurements is the wick-in-needle technique 
where a system based on a needle filled with a nylon wick is used to measure IF[11, 12, 
81, 82]. This method has been applied in a number of studies [12, 13, 25, 82] most 
notably by Taghian et al. that used the wick in needle to monitor IFP treatment response 
to paclitaxel and doxorubicin in breast cancers as part of a hypothesis generating study 
[2]. Recently, this method has been modified so that the wick is replaced with a fiberoptic 
pressure transducer  which is still as invasive as before [83-85]. Both methods are 
calibrated through a water column before use, which is not an option for SHAPE unless 
the tumor is superficial as tissue attenuation could otherwise affect the results [80, 84]. 
However, SHAPE offers the indisputable benefit over these needle based methods of 
reducing patient discomfort as it is noninvasive. Other methods that have been studied for 
IFP measurements are micropuncture using glass capillaries; this method is accurate, but 
only practical for superficial tumors as measurements are limited to 1 mm below the 
surface (Heldin 2004) [12] and lastly, scanning acoustic microscopy, that has only been 
tested ex vivo and is therefore not clinically practical.  
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 There has been no calibration of tumor IFP to date using SHAPE and therefore 
this is a substantial addition to the field. The conditions of specific aim 3 are met in all 
aspects save one, as a significant linear relationship was seen and a successful calibration 
implemented on the modified software designed by us for the Sonix RP. However, the 
correlation condition set in specific aim 3 was not met as the highest correlation was r = -
0.69 whereas our hypothesis stated it could be up to -0.75. Nevertheless, a correlation 
coefficient of -0.69 is close to what is seen in the literature [57] and perhaps more than 
anything else an indication of unrealistic expectations when designing the study.  
4.4 Paclitaxel Treatment in a Murine Model 
 The ability of SHAPE to estimate IFP for treatment monitoring was tested by 
administering the chemotherapy agent paclitaxel to female nude athymic rats with MDA - 
MB - 231 breast cancer xenografts. Conditions were set to best simulate chemotherapy 
regimens currently used in humans (Taghian et al. 2005) and the animals were divided 
into three treatment and control groups corresponding to three different days of paclitaxel 
injection (day 21, 24 and 28). The effects on subharmonic amplitude, IFP and volume 
were measured and the results of this work and analyses with regard to time and 
treatment are presented in sections 4.4.1 through 4.4.4 and discussed in section 4.4.5. 
4.4.1 Relationship between Subharmonic Amplitude and IFP 
 Of the 64 rats injected with MDA-MB-231 for the treatment studies 34 (53%) 
exhibited tumor growth and 26 (40%) were successfully imaged. We established an 
inverse linear relationship for the three thresholds (r: -0.72 to -0.74, p < 0.01). This is a 
higher correlation than was seen in the calibration study (r: -0.60 to -0.69, p < 0.01) and 
is likely due to the increased number of rats. However, the difference in correlation was 
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not significant (p > 0.25). For consistency, the linear regression analysis was repeated 
after removing the two data points where the standard deviation for IFP was higher than 5 
mmHg as was done in the calibration study. A linear regression analysis was also 
performed after removing data points where the ratio of standard deviation to the mean 
(standard deviation/mean) of three data points was larger than 50% and where it was 
larger than 100% (see appendix I).  
 The highest correlation was at 100% (r = -0.74, p < 0.01) and it did not make a 
difference whether or not, points where the standard deviation for IFP was higher than 5 
mmHg were removed, which is not surprising given that two data points are only 1.9% of 
the 104 data points studied (table 4.4.). Moreover, the correlation for all three thresholds 
was equivalent (p > 0.76). Thus, further studies are needed before selecting an optimal 
threshold for SHAPE measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
87 
Table 4.4 Equations derived from linear regression analysis 
Threshold IFP standard deviation 
> 5 mmHg included 
[mmHg] 
(r, p, n) IFP standard deviation 
> 5 mmHg not included 
[mmHg] 
(r, p, n) 
100% 
𝐼𝐹𝑃 =  
SHA − 117.3
−0.9016
 
r = -0.74, 
p < 0.01 
n = 104 
𝐼𝐹𝑃 =  
SHA − 117.59
−0.9071
 
 
r = -0.74,  
p < 0.01,  
n = 102 
115% 
𝐼𝐹𝑃 =  
SHA − 129.28
−0.9229
 
r = -0.73, 
p < 0.01, 
n = 104 
𝐼𝐹𝑃 =  
SHA − 129.28
−0.9098
 
 
r = -0.72,  
p < 0.01, 
 n = 102 
130% 
𝐼𝐹𝑃 =  
SHA − 143.87
−1.0359
 
r = -0.72, 
p < 0.01, 
n = 104 
𝐼𝐹𝑃 =  
SHA − 144.21
−1.0407
 
 
r = -0.72, 
p < 0.01, 
n = 102 
Table 4.4. Equations derived from linear regression analysis at all three thresholds. Results for both the 
case using all data points and the case eliminating data points where the standard deviation for IFP was 
larger than 5 mmHg are reported. For the analysis we used the actual values rather than relative values as 
they might skew the data when applying the equations to an independent dataset. IFP stands for interstitial 
fluid pressure and SHA stands for subharmonic amplitude 
 
 
 
An inverse linear relationship was seen at the 100% threshold between subharmonic 
amplitude and IFP where the following equation was derived to estimate pressure: 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟏𝟕.𝟑
−𝟎.𝟗𝟎𝟏𝟔
 (4.7) 
Figure 4.31 shows this inverse linear relationship with original values and relative values 
(0 dB corresponding to the lowest dB value and the subharmonic amplitude difference 
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relative to that value is reported) can be seen in figure 4.32 for a clearer comparison. For 
consistency, two data points with standard deviation higher than 5 mmHg were removed 
as was done in the calibration study resulting in the following pressure estimation 
equation. 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟏𝟕.𝟓𝟗
−𝟎.𝟗𝟎𝟕𝟏
 (4.8) 
The two equations are very similar and the correlation is the same whether the two data 
points have been removed or not as they only constitute 1.9% of the data. The slopes (p = 
0.40) and intercepts (p = 0.94) were not significantly different. As before, one graph 
shows the inverse linear relationship with original values (figure 4.33) and the other with 
values relative to the lowest subharmonic amplitude for clarity (figure 4.34).  
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Figure 4.31 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold 
 
 
 
 
Figure 4.32 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. Note 
that for a clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest 
dB value and then subharmonic amplitude difference relative to that value is reported). 
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Figure 4.33 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. 
 
 
 
 
Figure 4.34 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this 
case data points with IFP standard deviation larger than 5 mmHg have been eliminated. Note that for a 
clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB value 
and then subharmonic amplitude difference relative to that value) is reported. 
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 An inverse linear relationship was seen between subharmonic amplitude and IFP 
for the 115% threshold and the following equation was derived to estimate pressure: 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟐𝟗.𝟐𝟖
−𝟎.𝟗𝟐𝟐𝟗
 (4.9) 
Figure 4.35 shows this relationship with original values and relative values (0 dB 
corresponding to the lowest dB value and the subharmonic amplitude difference relative 
to that value is reported) can be seen in figure 4.36. As before, two data points with 
standard deviation higher than 5 mmHg were removed resulting in the following pressure 
estimation equation:  
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟐𝟗.𝟐𝟖
−𝟎.𝟗𝟎𝟗𝟖 
 (4.10) 
The two equations are nearly identical (p =  0.96 for slope and p = 0.83 for offset) as is 
the correlation. Figure 4.37 shows the inverse linear relationship after removing the data 
points where the standard deviation for IFP was higher than 5 mmHg with original values 
and figure 4.38 with values relative to the lowest subharmonic amplitude.  
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Figure 4.35 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. 
 
 
 
 
Figure 4.36 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. Note 
that for a clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest 
dB value and then subharmonic amplitude difference relative to that value is reported). 
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Figure 4.37 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. 
 
 
 
 
Figure 4.38 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this 
case data points with IFP standard deviation larger than 5 mmHg have been eliminated. Note that for a 
clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB value 
and then subharmonic amplitude difference relative to that value) is reported. 
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 An inverse linear relationship was seen between subharmonic amplitude and IFP 
for the 130% threshold and the following equation was derived to estimate pressure: 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟒𝟑.𝟖𝟕
−𝟏.𝟎𝟑𝟓𝟗
 (4.11) 
as seen in figure 4.39 with original values and figure 4.40 with values relative to the 
lowest subharmonic amplitude. After removing points where IFP standard deviation was 
higher than 5 mmHg the following equation was derived: 
 𝑰𝑭𝑷 =  
𝑺𝑯𝑨−𝟏𝟒𝟒.𝟐𝟏
−𝟏.𝟎𝟒𝟎𝟕
 (4.12) 
as seen in figure 4.41 with original values and figure 4.42 with relative values. The slopes 
(p = 0.78) and intercepts (p = 0.72) were not significantly different. 
 
' 
 
 
Figure 4.39 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. 
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Figure 4.40 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. Note 
that for a clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest 
dB value and then subharmonic amplitude difference relative to that value) is reported. 
 
 
 
 
Figure 4.41 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this 
case data points with a IFP standard deviation larger than 5 mmHg have been eliminated. 
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Figure 4.42 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this 
case data points with IFP standard deviation larger than 5 mmHg have been eliminated. Note that for a 
clearer comparison relative values for subharmonic amplitude (0 dB corresponding to the lowest dB value 
and then subharmonic amplitude difference relative to that value) is reported. 
 
 
 
 As was expected from the calibration phase of the study all three thresholds are 
significantly different (p < 0.01). The differences between groups (100% & 115%, 100% 
& 130%, 115% & 130%) are also statistically significant (p < 0.01 for all). A box plot of 
the subharmonic data per threshold is shown in figure 4.43 and a plot of the comparison 
interval for all three thresholds in figure 4.44. The mean for the subharmonic amplitude 
was 110 ± 11.7 dB, 122.0 ± 12.4 dB and 135.5 ± 14.4 dB for 100%, 115% and 130% 
threshold levels, respectively. 
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Figure 4.43 Box plot of the subharmonic data per threshold. All groups are significantly different from 
each other. 
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Figure 4.44 Graph showing the means for all three thresholds and how none of their comparison intervals 
overlap thereby showing that they are all significantly different. 
 
 
 
 The slopes and intercepts of the calibration equations were compared to the slopes 
and intercepts of the treatment equations to estimate whether a universal model could be 
derived. No significant differences were seen and therefore a universal equation could 
potentially be derived for future pressure estimation. This is further supported by the fact 
that there was no statistically significant difference (p > 0.14 ) between the calculated and 
measured IFP at 115% threshold in section 4.3.2. The results of this comparison can be 
found in table 4.5. 
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Table 4.5 Comparison of slopes and intercepts for calibration and treatment 
Threshold p value for slopes p value for intercepts 
100% 0.40 0.94 
115% 0.67 0.29 
130% 0.47 0.94 
Table 4.5. p values from the comparison of calibration equations and the corresponding equations for 
treatment at 100%, 115% and 130% thresholds. 
 
 
 
 Linear regression analysis was used to investigate the subharmonic data 
depending on the day of treatment (day 21, 24 and 28). All three thresholds were 
considered (100%, 115% and 130%) for each day. An inverse linear relationship (r: -0.63 
to -0,78, p < 0.01, n = 34) was seen in all cases. The highest correlation was found at 
115% threshold on day 28 (r = -0.78, p < 0.01, n = 34). The results for day 21 can be seen 
in figures 4.45, 4.46 and 4.47 for thresholds 100%, 115% and 130% respectively.  
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Figure 4.45 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 21 day group for threshold 100%. 
 
 
 
 
Figure 4.46 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 21 day group for threshold 115%. 
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Figure 4.47 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 21 day group for threshold 130%. 
 
 
 
 The results for day 24 can be seen in figure 4.48, 4.49 and 4.50 for thresholds 
100%, 115% and 130% respectively.  
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Figure 4.48 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 24 day group for threshold 100%. 
 
 
 
 
Figure 4.49 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 24 day group for threshold 115%. 
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Figure 4.50 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 24 day group for threshold 130%. 
 
 
 
 The results for day 28 can be seen in figure 4.51, 4.52 and 4.53 for thresholds 
100%, 115% and 130% respectively. 
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Figure 4.51 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 28 day group for threshold 100%. 
 
 
 
 
Figure 4.52 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 28 day group for threshold 115%. 
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Figure 4.53 Subharmonic amplitude results compared to the pressure monitor measurements from rats in 
the 28 day group for threshold 130%. 
 
 
 
4.4.2 Differences in Subharmonic Amplitude Compared to Differences in IFP 
  No significant relationship was seen when looking at the difference in 
subharmonic amplitude between tumor and tissue and comparing it to the difference in 
IFP between tumor and tissue for thresholds 100% (p = 0.19), 115% (p = 0.22) and 130% 
(p = 0.16). The average difference in IFP between tumor and tissue was 13.97 ± 6.72 
mmHg and the average difference in subharmonic amplitude between tumor and tissue 
was: -16.49 ± 9.62 dB (100%), -18.76 ± 8.33 dB (115%) and -20.29 ± 9.97 dB (130%). 
Note that n = 51 as there are 26 rats and for each rat both tumor and tissue IFP were 
measured pre and post treatment except in one rat where no post measurement was taken, 
so n = 26*2 - 1 = 51. See figures 4.54, 4.55 and 4.56, respectively. 
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Figure 4.54 Results for the difference in subharmonic amplitude between tumor and tissue compared to the 
difference in IFP between tumor and tissue for the 100% threshold. 
 
 
 
 
Figure 4.55 Results for the difference in subharmonic amplitude between tumor and tissue compared to the 
difference in IFP between tumor and tissue for the 115% threshold. 
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Figure 4.56 Results for the difference in subharmonic amplitude between tumor and tissue compared to the 
difference in IFP between tumor and tissue for the 130% threshold. 
 
 
 
 The average subharmonic amplitude for the treatment group was 0.36 ± 12.60 dB 
(100%), 0.84 ± 11.76 dB (115%) and -1.21 ± 15.44 dB (130%) and for the control group 
the average subharmonic amplitude was -1.41 ± 9.62 dB (100%), -1.79 ± 9.21 dB (115%) 
and -2.47 ± 8.56 dB). Furthermore, there was no significant difference between the 
treatment and control groups at 100% threshold (p = 0.76), 115% threshold (p = 0.62) or 
the 130% threshold (p = 0.85).  
 Moreover, no significant difference (p = 0.15) in tumor IFP was seen between the 
rats before and after treatment with tumor IFP decreasing from 15.3 ± 7.0 mmHg to 12.6 
± 6.2 mmHg after the paclitaxel treatment. Linear regression analysis of the difference in 
subharmonic amplitude pre and post treatment when compared to difference in IFP pre 
and post treatment showed no statistically significant relationship for thresholds 100% (p 
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= 0.6), 115% (p = 0.8) and 130 % (p = 0.4). The data is plotted out for the three 
thresholds in figures 4.57 to 4.59.  
 
 
 
 
Figure 4.57 Comparison of the difference in subharmonic amplitude before and after treatment compared 
to the difference in IFP before and after treatment for the 100% threshold. 
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Figure 4.58 Comparison of the difference in subharmonic amplitude before and after treatment compared 
to the difference in IFP before and after treatment for the 115% threshold. 
 
 
 
 
Figure 4.59 Comparison of the difference in subharmonic amplitude before and after treatment compared 
to the difference in IFP before and after treatment for the 130% threshold. 
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 These differential analyses indicate that no clear relationship can be seen. It is not 
possible to arrive at a decision on the feasibility of looking at the ratio of change in 
subharmonic amplitude from before treatment to post treatment as a marker for response 
as the power of this study is not adequate to measure the effect of the paclitaxel. The 
original sample size for this study was carried out with a two sample t-test where the null 
hypothesis (H0) was defined as no difference between groups. Assuming 0.8 power, α = 
0.05 and the control group having a mean IFP of 6.9 mmHg and the paclitaxel treatment 
group having a mean IFP of 4.4 mmHg and standard deviation of 1.8 mmHg a sample 
size of 6 was derived for the control group and a sample size of 20 was derived for the 
treatment group. This analysis was carried out using the .sampsi command in Stata. 
Originally, we were planning for groups of 7 and 23 animals and assuming the change 
due to paclitaxel will be from 6.9 to 4.4 mmHg (with standard deviations around 1.8 
mmHg) and so the analysis would have over 80 % statistical power. However, for the 
treatment groups (for days 21, 24 and 28) 60 rats received injections of the breast cancer 
cells, which resulted in 38 animals with tumors and amongst those 26 were successfully 
imaged.  The 15 rats with tumor growth that failed the imaging study were mainly for 
technical reasons (the experimental software on the Sonix RP crashed occasionally).  The 
treatment groups therefore ended up containing 8, 9 and 9 rats for 21, 24 and 28 days 
post-implantation, respectively.  In each group there were 2 rats that were designated as 
control cases (i.e., they did not receive injections of paclitaxel).  Using the experimental 
numbers for IFP pre and post treatment, results in a 64% power when the IFP goes down 
from 15.3 to 12.6 mmHg after the paclitaxel treatment with a standard deviation of 6.7 
mmHg. Therefore, it is vital that any future studies in a murine model should scan 90 rats 
111 
with tumors which would mean injecting at least 142 rats (with a 63% take rate that 
would lead to 90 rats with tumors), preferably more. 
 Figure 4.60 depicts the change in IFP from pre to post treatment. The change 
encountered for the control animals have also been included. The standard deviations are 
quite large, but for the IFP values a clear trend is seen with the IFP reducing more as time 
increases. However, there was no statistically significant (p = 0.95) difference between 
IFP before and after treatment for the control and treatment groups and thus no treatment 
response for the SHAPE method to monitor. The difference in IFP from pre to post 
treatment for each rat in both the control and treatment groups can be seen in figure 4.61.  
 
 
 
 
Figure 4.60 The change in tumor IFP from pre to post administration of paclitaxel. Notice how the 
treatment results in lower IFP values at days 24 and 28, as expected. 
 
-25.00
-20.00
-15.00
-10.00
-5.00
0.00
5.00
10.00
15.00
21 24 28
ch
an
ge
 in
 IF
P
 p
re
 t
o
 p
o
st
 [
m
m
H
g]
 
days 
treatment
control
112 
 
Figure 4.61 The difference in IFP from pre to post treatment for each rat in both the control and treatment 
groups. 
 
 
 
 For day 21 there is an increase in subharmonic amplitude for all groups except the 
treatment group at 100% threshold (Figure 4.62). This increase in subharmonic amplitude 
indicates a decrease in IFP as is expected but as for day 21 which is consistent in the 
control group (IFP ↓) but not in the treatment group (IFP ↑). However, this increase was 
only 1 mmHg and the standard deviation is high so no conclusion can be drawn from this 
113 
group. On day 24 the IFP decreased for the treatment group by 2.2 mmHg but increased 
by 0.5 mmHg for the control group. The subharmonic amplitude (Figure 4.63) decreased 
as well at all threshold levels which is not consistent with the calibration equations from 
section 4.3.2. Day 28 is the only day where the change in IFP decrease was consistent 
with the change in subharmonic amplitude (Figure 4.64) at all thresholds i.e., IFP 
decreased and subharmonic amplitude increased correspondingly. For comparison the 
change in subharmonic amplitude is also presented for each threshold level in figures 
4.65. (100%), 4.66 (115%) and 4.67 (130%). 
 
 
 
Figure 4.62 The change in tumor subharmonic amplitude from pre to post administration of paclitaxel at 
day 21. Notice how the treatment results in an increase for all thresholds except the treatment group at 
100% threshold. 
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Figure 4.63 The change in tumor subharmonic amplitude from pre to post administration of paclitaxel at 
day 24. Note how the treatment results in a decrease for all thresholds both for the treatment and control 
groups. 
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Figure 4.64 The change in tumor subharmonic amplitude from pre to post administration of paclitaxel at 
day 28. Notice how the treatment results in an increase for all thresholds for both treatment and control. 
 
 
 
 
Figure 4.65 The change in tumor subharmonic amplitude from pre to post administration of paclitaxel at a 
100% threshold grouped by day. 
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Figure 4.66 The change in tumor subharmonic amplitude from pre to post administration of paclitaxel at a 
115% threshold grouped by day. 
 
 
 
 
Figure 4.67 The change in tumor subharmonic amplitude from pre to post administration of paclitaxel at a 
115% threshold grouped by day. 
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4.4.3 Interstitial Fluid Pressure  
 The average level of IFP seen in the rat tumors was 14.0  ± 6.7 mmHg. No 
difference (p = 0.98) in tumor IFP was seen depending on which day the pressure was 
measured with averages 8.9  ± 9.4 mmHg (day 21), 7.1 ± 7.9 mmHg (day 24) and 8.0 ± 
8.4 mmHg (day 28). Figure 4.68 shows a box plot of the means for all three groups: day 
21 (n = 8 rats), day 24 (n = 9 rats) and to day 28 (n = 9 rats). A plot of the comparison 
interval for all three days is shown in figure 4.69. The tumor IFP for days 21 and 24 (p = 
0.99), 21 and 28 (p = 0.98), 24 and 28 (p = 1.0), was also not significantly different. 
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Figure 4.68 Box plot of IFP per day. None of the groups are significantly different from each other. 
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Figure 4.69 Graph showing the mean IFP for all three days and how all comparison intervals overlap 
thereby showing that none of them are significantly different. 
 
 
 
 There was a significant difference (p = 0.025) in IFP between the control group of 
rats (n = 6 rats) and the rats treated with paclitaxel (n = 19 rats)  
4.4.4 Tumor Volume 
 The average volume in the tumors was 444.25 ± 309.65 mm
3
. No significant 
relationship (p = 0.43) was seen between tumor volume and tumor IFP (Figure 4.70). 
This is consistent with the results of the proof of concept and calibration studies (cf., 
Figure 4.5 and Figure 4.30). 
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Figure 4.70 No significant relationship was found between tumor volume and tumor pressure. 
 
 
 
 Analysis using one way ANOVA showed no difference in volume (p = 0.23) 
depending on which day the tumors were examined (day 21, 24 or 28). Figure 4.71 
depicts a box plot of the means for all three groups: day 21 (n = 8 rats), day 24 (n = 9 
rats) and day 28 (n = 9 rats). A plot of the comparison interval for all three days is shown 
in figure 4.72. The difference in volume between days 21 and 24 (p = 0.26), 21 and 28 (p 
= 0.34), 24 and 28 (p = 0.98), was also not statistically significant  
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Figure 4.71 Box plot of volume per day. None of the groups are significantly different from each other. 
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Figure 4.72 Graph showing the means in volume for all three days and how all comparison intervals 
overlap thereby showing that none of them are significantly different. 
 
 
 
 No difference (p = 0.59) in volume was seen between the control group of rats (n 
= 6 rats) and the rats treated with paclitaxel (n = 19 rats). No difference (p = 0.81) in 
volume was seen between the rats before and after treatment when looking at all the data 
combined. Figure 4.73 demonstrates that when looking at each day separately the tumors 
shrink in size two days after the paclitaxel injection for treatment days 21 and 24. The 
tumors also reduced for the control group on day 24, but it must be noted that only one 
rat was in the control group. 
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Figure 4.73 The change in tumor volume from pre to post administration of paclitaxel.  Notice how the 
treatment results in lower IFP values at days 24 and 28, as expected. 
 
 
 
4.4.5 Discussion for Paclitaxel Treatment in a Murine Model 
 As was expected from the calibration study an inverse linear relationship was 
observed between the subharmonic amplitude and the IFP for all three thresholds (r: -
0.72-0.74, p < 0.01, n = 104). Removing points where the standard deviation for IFP was 
higher than 5 mmHg did not improve the correlation. All thresholds were significantly 
different from each other. This is consistent with the results of the calibration study and it 
should be noted that the intercepts for the equations derived for calibration are very 
similar to the ones from the treatment study and the slopes (see table 4.5). This suggests 
that a calibration curve could be used to estimate IFP at least when using the same agent, 
scanner and acoustic parameters for the same tumor type.  
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 There was no statistical difference in subharmonic amplitude between the control 
and treatment groups. Furthermore, the change in subharmonic amplitude only 
corresponded to the change in tumor IFP on day 21 where the change in subharmonic 
amplitude was positive, indicating a decrease in IFP as was seen in the measured values. 
However, on days 24 and 28 a decrease in both subharmonic and IFP and an increase in 
both subharmonic and IFP was seen respectively. This indicates that there is no effect of 
the treatment and thus impossible to make any assumptions on whether or not SHAPE is 
sensitive enough to estimate changes in IFP for treatment monitoring. Moreover, there 
were no significant changes in IFP between days and no significant changes pre to post 
treatment. It could be that the low number of rats, due to technical difficulties,  resulted in 
the power of the study not being high enough to pick up the somewhat small effect of the 
paclitaxel.  Furthermore, paclitaxel is more toxic to rats than to humans. The dose given 
was only 25% (5 mg/kg instead of 20 mg/kg) of what is normally used in humans as that 
is the highest safe paclitaxel dose for rats [63]. This might also have contributed to the 
lack of effect from the chemotherapy. There were no significant changes in volume at all 
and no relationship was seen between volume and IFP. This corresponds to studies in 
murine models and clinical studies [2, 25].  
 SHI depicted the tortuous morphology of tumor neovessels better than 
fundamental US imaging, due to the suppression of tissue signals. However, the degree of 
tissue suppression was less than other in vivo studies undertaken by our group [44, 72, 
86], which was attributed to the nonlinear transfer function of the scanner. Other, 
potential limitations to our experiments included that the angiogenesis in MDA - MB - 
231 tumor varies and thus, not all tumors were vascular. Moreover, flow rate, bubble 
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destruction and bubble concentration are factors, which may have confounded the 
efficacy of SHAPE.  
 The average level of IFP seen in the rat tumors was 14.0 mmHg which is 
comparable to tumor IFP levels seen by Ferretti et al. in a rat tumor model with BN472 
breast cancer xenografts [25], but considerably higher than what we expected to see from 
human studies as Taghian et al. saw a mean level of 6.9 mmHg but a similar decrease 
(2.5 mmHg and 2.7 mmHg) in tumor IFP after the paclitaxel treatment [2]. They also 
noted that a decrease in IFP seen after 2 to 3 days was a precursor for changes in tumor 
volume in rats. As the rats were euthanized 2 days after paclitaxel administration we did 
not get a chance to investigate this. Ferretti also noted that IFP is dependent on the host 
vasculature, especially blood volume and suggested that IFP can be used as a viable 
marker for treatment monitoring [25].  
 This is the first study on the use of SHAPE in a tumor model and despite its 
limitations valuable information was gathered that will benefit future studies. The 
calibration equations derived indicate that although accurate pressure estimates were not 
achieved in this study, the monitoring of breast cancer response to neoadjuvant 
chemotherapy can be achieved with proper calibration. It is likely that relative pressure 
estimates (i.e., the ratio of tumor subharmonic to the subharmonic of surrounding normal 
tissues) are achievable using a scanner with a higher degree of tissue suppression, but that 
needs to be further investigated in future studies. For now, the calibration should provide 
sufficient information to impact clinical management and clinical studies in humans are 
already underway in our laboratory using a Logiq 9 scanner.  
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5 CONCLUSIONS AND FUTURE RECOMMENDATIONS 
5.1 Conclusions and Contributions to Science 
 SHAPE has been evaluated as a tool for IFP estimation in breast cancer during 
neoadjuvant chemotherapy. There have been no prior studies looking into the use of 
noninvasive US based methods for IFP estimation. Furthermore, this is the first study 
where SHAPE has been investigated in vivo at frequencies higher than 5 MHz and the 
first time using SHAPE in microvessels. Although a number of studies have looked at 
SHAPE in vitro and in vivo in other animal models and humans and have provided an 
indication that IFP estimation is possible they are not applicable to tumor IFP  
measurements as they are generally at a lower frequency and do not address the problems 
specific to tumor vasculature and the tumor IFP range. 
 The project was divided into four different phases each designed to address a 
certain aspect of the evaluation; an in vitro study in a water-tank, an in vivo proof of 
concept in a swine melanoma model, a calibration in a murine model and finally 
paclitaxel treatment in a murine model. Specific aim 1 was aimed at assessing the 
subharmonic changes over a pressure range of 0 to 50 mmHg which is the IFP range most 
commonly encountered in tumors. The experiments were carried out on a commercially 
available scanner at frequencies employed for breast cancer scanning to simulate the 
clinical environment. The conditions of the hypothesis set forward in specific aim 1 were 
met, namely that an inverse linear relationship with an absolute correlation higher than 
0.9 could be seen between the subharmonic amplitude and the hydrostatic pressure. Using 
our experience from the in vitro studies we were able to validate the SHAPE method in 
vivo in a proof of concept study in swine melanomas thereby fulfilling specific aim 2 i.e., 
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a significant inverse linear relationship between IFP and subharmonic amplitude with an 
absolute r-value above 0.75 was obtained in vivo in a swine model and the feasibility of 
using SHAPE to estimate IFP in tumors was established. The results of specific aims 1 
and 2 were published in Ultrasonics [76]. 
 After the initial feasibility studies a murine model with breast cancer xenografts 
was developed in order to calibrate and test SHAPE for pressure estimations. For specific 
aim 3 a new software solution was successfully developed and implemented on a 
commercial scanner for the purpose of SHI and investigating SHAPE in tumors. This 
modified solution was used to calibrate the SHAPE method in a rat model. The 
conditions set in specific aim 3 were not fully met as the greatest correlation was -0.69 
and the hypothesis stated that a correlation of -0.75 could be achieved. However, in 
specific aim 4 where a greater number of subjects was investigated a correlation of -0.74 
was attained suggesting that the relationship between subharmonic amplitude and IFP can 
be utilized for pressure estimation. The equations derived from the linear regression 
analysis in the calibration phase were applied to an independent data set from the 
treatment phase with very promising results as no statistically significant difference was 
seen between the measured and calculated IFP values at a 115% threshold giving further 
support to the validity of tumor SHAPE and a very good reason to continue 
investigations.  
 In specific aim 4, paclitaxel chemotherapy was administered to study if SHAPE 
could distinguish the IFP lowering effect of treatment. When using a differential 
approach i.e., looking at the difference in subharmonic amplitude from before and after 
paclitaxel administration, no effect was observed. There was also no statistically 
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significant difference in IFP before and after treatment. This lack of effect is most likely 
due to the low paclitaxel dose, as it was only 25% of the dose given to humans. 
Therefore, no decision can be made whether or not SHAPE is sensitive enough for 
monitoring cancer treatment by estimating IFP at this time and further studies are needed. 
Nevertheless, the calibration results give hope that if a suitable calibration method for 
individuals can be found, absolute pressure values can be used instead of the relative 
values that the differential analysis would provide.  
 Results from this study demonstrate that SHAPE may be useful for the 
noninvasive monitoring of IFP. If proven viable, SHAPE has the potential to provide 
benefits for cancer therapy as it is noninvasive and thus, there is less risk and more 
comfort for the patient than with the wick-and-needle method. Moreover, it would make 
it easier to customize individual patient treatment if SHAPE were found to be able to 
monitor neoadjuvant treatment response throughout the chemotherapy cycles. 
5.2 Future Recommendations 
 For future studies investigating the effect of paclitaxel and monitoring of tumor 
SHAPE a larger number of animals and a different animal model that can tolerate the 
same dosage of paclitaxel as humans is recommended. Mice can sustain a maximum dose 
of 20 mg/kg which is the same as for humans and have a similar pharmokinetic behavior 
as humans with paclitaxel [87]. Furthermore, tumor vasculature is erratic and pressure 
within smaller vessels could not be optimally distinguished. These potential problems 
could be eliminated by using a scanner offering higher resolution for SHI than the one 
used for this study. 
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 SHAPE as a method for tumor IFP estimation and treatment monitoring could be 
visualized in a number of manners. The results could be represented by a single tumor 
IFP number or a color overlay, with a pressure map over the subharmonic image showing 
where IFP is raised, could serve as both a monitoring tool and a method for tumor 
localization. IFP rises quickly in the periphery of tumors and thus if SHAPE showed a 
sharp increase in IFP that could indicate a tumor and call for further investigation in that 
area. Studies in different locations such as cervical cancer, skin, rectal, lymph nodes and 
others could also be carried out using SHAPE. To conclude, the results of this first study 
on the use of SHAPE to estimate IFP in tumors indicate great promise for tumor IFP 
estimation and monitoring of chemotherapy.  
 Currently, a clinical study on SHI in human breast cancer is underway and IFP 
estimation is part of that investigation, building on the results of this study using a Logiq 
9 scanner with encouraging results indicating that SHAPE IFP tumor estimates could 
become an additional marker in the monitoring of neoadjuvant chemotherapy in breast 
cancer. To conclude, the results of this first study on the use of SHAPE to estimate IFP in 
tumors indicate great promise for tumor IFP estimation and monitoring of chemotherapy. 
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Appendix A: Algorithm for In Vitro Studies and In Vivo Proof of Concept 
 
 
 
 
Algorithm for the fast Fourier transform 
function [fft_sig] = fft_signal2(sig); 
p=nextpow2(length(sig)); 
N=2^(p+2); 
F= [0 : N - 1]/N;  
X=abs(fft(sig,N)); 
XX=fftshift(X); 
FF = [-N/2:N/2-1]/N;XX=fftshift(X); 
FFF = FF*20; 
fft_sig = [FFF((N/2+1):end);XX((N/2+1):end)']'; 
 
smooth1(X, q) is a smoothing function supplied by Dr. Flemming Forsberg 
function Y = smooth1(X,q) ; 
 
Algorithm for subharmonic extraction at 4.5 MHz over a bandwidth of 1 MHz 
function [output]=shape101_averageauto_9(rfdata) 
  
    data=rfdata; 
    loc=find(data(:,1)>4.0 & data(:,1)<5.0); 
    red_data=data(loc,:); 
    output=mean(red_data(:,2)); 
139 
%     output=20*log10(output(:,1)); 
 
Algorithm for fundamental extraction at 9 MHz over a bandwidth of 1 MHz 
function [output]=shape101_averageauto_fun_9(rfdata) 
  
    data=rfdata; 
    loc=find(data(:,1)>8.5 & data(:,1)<9.5); 
    red_data=data(loc,:); 
    output=mean(red_data(:,2)); 
    output=20*log10(output(:,1)); 
    
 
Code for execution of data processing 
 
clear all 
close all 
  
[filename, pathname] = uigetfile('*.rf','Select a rf file', 
'MultiSelect','on'); 
cd(pathname); 
sz = size(filename); 
numfiles = sz(2); 
  
dialog = inputdlg('Enter number of frames to be considered:'); 
nfr = str2num(dialog{1}); 
  
sub_array = zeros(numfiles,5); 
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textHeader = {'Filename', 'Sample #', 'Exact 9', 'Average 9', 'Exact 
6', 'Average 6', 'Fundamental'}; 
  
for i = 1:numfiles; 
     
    [image,header] = RPread(filename{i});  
    sampling_freq = header.sf/1000000; 
    rfdata=image; 
    sz=size(rfdata); 
    subharmonic = zeros(floor(sz(1)/10),sz(2),sz(3)); 
    si = num2str(i); 
%     Figure this out! 
%     sub_array(i,1) = filename{i}; 
    sub_array(i,1) = i; 
     
    for l = 1:nfr; 
        m = 1; 
         for k = 1:100:(sz(1)-100) 
            for v = 1:sz(2) 
                rfdata_window = rfdata(k:(k+100), v, l); 
                rfdata_fft(:,:)=fft_signal2(rfdata_window(:,:)); 
                rfdata_fft_log = 20*log(rfdata_fft(:,2)); 
                rfdata_fft_log = smooth1(rfdata_fft_log, 15); 
                rfdata_fft_array(:,m,v,l) = rfdata_fft_log; 
                
                harmonics = [rfdata_fft(:,1) rfdata_fft_log]; 
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                %NB. For 10 MHz use 4.5 MHz and 3 MHz, for 6.7 MHz use 
3 MHz 
                %(using FFT from august 23 2010 
      
                %Exact value for 9 MHz transmit pulse 
                loc9 = find(rfdata_fft(:,1) == 4.3750); 
                subharmonic_exact_9(m,v,l) = rfdata_fft_log(loc9); 
  
                %Exact value for 6 MHz transmit pulse 
                loc6 = find(rfdata_fft(:,1) == 3.125); 
                subharmonic_exact_6(m,v,l) = rfdata_fft_log(loc6); 
  
                %Average method for 9 MHz transmit pulse 
                subharmonic_avg_9(m,v,l) = 
shape101_averageauto_9(harmonics); 
  
                %Average method for 6 MHz transmit pulse 
                subharmonic_avg_6(m,v,l) = 
shape101_averageauto_6(harmonics); 
                 
                %Average method for 9 MHz fundamental 
                subharmonic_avg_fun_6(m,v,l) =  
shape101_averageauto_fun_6(harmonics); 
                
             end 
            m = m+1; 
        end 
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        %B image 
        figure 
        imagesc(abs(hilbert(image(:,:,l)))) 
        colormap(gray) 
        sl = num2str(l); 
        fig_title = strcat('B Image - Frame ', sl, ' - File ', si); 
        title(fig_title) 
        fig_name = strcat('B Image - Frame ', sl, ' - File ', si, 
'.jpg'); 
        saveas(gcf,fig_name) 
  
        %Subharmonic image for Exact 9 MHz method 
        figure 
        colormap(jet) 
        imagesc(subharmonic_exact_9(:,:,l)) 
        colorbar; 
        fig_title = strcat('Exact method 10 MHz 9 - 4.5 - Frame ', sl, 
' - File ', si); 
        title(fig_title) 
        fig_name = strcat('Exact method 10 MHz 9 - 4.5 - Frame ',sl, ' 
- File ', si, '.jpg'); 
        saveas(gcf,fig_name) 
  
        %Subharmonic image for Exact 6 MHz method 
        figure 
        imagesc(subharmonic_exact_6(:,:,l)) 
        colorbar; 
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        fig_title = strcat('Exact method 10 MHz 6 - 3 - Frame ', sl, ' 
- File ', si); 
        title(fig_title) 
        fig_name = strcat('Exact method 10 MHz 6 - 3 - Frame ',sl, ' - 
File ', si, '.jpg'); 
        saveas(gcf,fig_name) 
  
        %Subharmonic image for Average 9 MHz method 
        figure 
        imagesc(subharmonic_avg_9(:,:,l)) 
        colorbar; 
        fig_title = strcat('Average method 10 MHz 9 - 4.5 - Frame ', 
sl, ' - File ', si); 
        title(fig_title) 
        fig_name = strcat('Average method 10 MHz 9 - 4.5 - Frame ',sl, 
' - File ', si, '.jpg'); 
        saveas(gcf,fig_name) 
  
        %Subharmonic image for Average 6 MHz method 
        figure 
        imagesc(subharmonic_avg_6(:,:,l)) 
        colorbar; 
        sl = num2str(l); 
        fig_title = strcat('Average method 10 MHz 6 - 3 - Frame ', sl, 
' - File ', si); 
        title(fig_title) 
        fig_name = strcat('Average method 10 MHz 6 - 3 - Frame ',sl, ' 
- File ', si, '.jpg'); 
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        saveas(gcf,fig_name) 
    end 
  
    maxexa9 = max(max(max(subharmonic_exact_9))); 
    maxexa6 = max(max(max(subharmonic_exact_6))); 
    maxavg9 = max(max(max(subharmonic_avg_9))); 
    maxavg6 = max(max(max(subharmonic_avg_6)));  
    maxfun = max(max(max(subharmonic_avg_fun_6))); 
     
    %% 
    %------------------------------------------------------------------
---- 
    %ROI TEST STARTS 
    %------------------------------------------------------------------
---- 
  
%   imagesc(subharmonic_avg_6(:,:,1)) 
     
    %Insert x and y values for the sample to be investigated 
    x = 100; 
    y = 9; 
    sz = size(subharmonic_avg_6); 
  
    submean_avg_9 = zeros(1,sz(3)); 
    submean_avg_6 = zeros(1,sz(3)); 
    submean_exact_9 = zeros(1,sz(3)); 
    submean_exact_6 = zeros(1,sz(3)); 
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    submean_avg_fun_6 = zeros(1,sz(3)); 
  
    for g=1:sz(3); 
        submean_avg_9(g) = 
mean(mean(subharmonic_avg_9(y:(y+1),x:(x+125),g))); 
  
        submean_avg_6(g) = 
mean(mean(subharmonic_avg_6(y:(y+1),x:(x+125),g))); 
  
        submean_exact_9(g) = 
mean(mean(subharmonic_exact_9(y:(y+1),x:(x+125),g))); 
  
        submean_exact_6(g) = 
mean(mean(subharmonic_exact_6(y:(y+1),x:(x+125),g))); 
         
        submean_avg_fun_9(g) = 
mean(mean(subharmonic_avg_fun_6(y:(y+1),x:(x+125),g))); 
    end 
  
    exact_9_mean = mean(submean_exact_9); 
    exact_6_mean = mean(submean_exact_6); 
  
    avg_9_mean = mean(submean_avg_9); 
    avg_6_mean = mean(submean_avg_6); 
     
    avg_fun_6_mean = mean(submean_avg_fun_6); 
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    sub_array(i,2) = exact_9_mean; 
    sub_array(i,3) = avg_9_mean; 
    sub_array(i,4) = exact_6_mean; 
    sub_array(i,5) = avg_6_mean; 
     
    sub_array(i,6) = avg_fun_6_mean; 
      
     figure 
     plot(submean_avg_9) 
     fig_title = strcat('Average method 10 MHz 9 - 4.5 - ROI average 
per Frame - File ', si); 
     title(fig_title) 
     fig_name = strcat('Average method 10 MHz 9 - 4 - ROI average per 
Frame - File ', si, '.jpg'); 
     saveas(gcf,fig_name) 
  
     figure 
     plot(submean_avg_6) 
     fig_title = strcat('Average method 10 MHz 6 - 3 - ROI average per 
Frame - File ', si); 
     title(fig_title) 
      fig_name = strcat('Average method 10 MHz 6 - 3 - ROI average per 
Frame - File ', si, '.jpg'); 
     saveas(gcf,fig_name) 
  
     figure 
     plot(submean_exact_9) 
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     fig_title = strcat('Exact method 10 MHz 9 - 4.5 - ROI average per 
Frame - File ', si); 
     title(fig_title) 
      fig_name = strcat('Exact method 10 MHz 9 - 4 - ROI average per 
Frame - File ', si, '.jpg'); 
     saveas(gcf,fig_name) 
  
     figure 
     plot(submean_exact_6) 
     fig_title = strcat('Exact method 10 MHz 6 - 3 - ROI average per 
Frame - File ', si); 
     title(fig_title) 
     fig_name = strcat('Exact method 10 MHz 6 - 3 - ROI average per 
Frame - File ', si, '.jpg'); 
     saveas(gcf,fig_name) 
      
     %Writing to Excel 
     xlswrite('Processing.xls',textHeader, 'Summary') 
     xlswrite('Processing.xls',filename', 'Summary', 'A2') 
     xlswrite('Processing.xls',sub_array, 'Summary', 'B2') 
      
      
     %saving workspace 
     ws_name = strcat('workspace_', si, '.mat'); 
     save(ws_name) 
      
     close all 
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     clearvars -except i filename pathname numfiles sz nfr sub_array 
textHeader 
end 
  
beep 
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Appendix B: Procedure Protocol for Swine Melanoma Study 
 
 
 
 
Trial Protocol: Subharmonic-aided pressure estimation (SHAPE) of melanoma 
interstitial pressures 
 
Goals:  
To compare tumor interstitial SHAPE measurements with values obtained by Stryker 
pressure needle in a Swine melanoma model 
 
Procedure: 
1) After US measurements of primary and secondary lymph nodes have been 
completed, additional SHAPE study lasting roughly 20 minutes will be performed 
prior to surgical resection.  
2) Tumoral pressure levels will be obtained at three locations within the melanoma 
and three locations within the surrounding tissue and SHAPE measurements will 
be obtained at the needle tip using the Ultrasonix RP scanner (both in B and PW 
mode – 5 measurements per location in each mode).   
3) Lymph study will continue as normal with surgical ID and resection of nodes as 
well as confirmation of contrast within removed nodes. 
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4) Pressures from SHAPE measurements will be calculated and compared to Stryker 
measurements. 
Notes: 
1) An infusion of Definity  
2)  2 vials mixed and diluted in 50 ml saline  - 8 mins of infusion 
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Appendix C: Requirements and Specifications for Modified Sonix RP Solution 
SHAPE Requirements for Ultrasonix 
 
 
 
 
Rationale 
Systemic use of chemotherapy agents (alone or in combination with endocrine therapy) is 
widely used before surgery in the treatment of locally advanced, primary breast cancer 
(LABC) and is increasingly being employed to treat operable, palpable breast cancers as 
well.  By shrinking the breast tumors such neoadjuvant therapies can improve survival 
and reduce morbidity.  However, for these general benefits to be realized for the 
individual patient, it is essential to distinguish between tumors that respond to treatment 
and the ones that do not.  This requires a technique that noninvasively and reliably 
determines some physiologic measure of the breast cancer response to therapy.  The goal 
of this project is to improve the treatment of breast cancer by developing such a novel 
monitoring technique based on the innovative use of US imaging of specific signature 
signals from US contrast agents injected into the blood stream.  As an added benefit, the 
use of US contrast agents has already been approved by the Food and Drug 
Administration (for other indications) and there should therefore not be any significant 
risks associated with this new method.  Being able to monitor the in vivo response to 
therapy may also allow for better, individualized selection of treatment options (e.g., 
optimization of the available therapeutic agents). In this document the requirements for 
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the implementation of subharmonic aided pressure estimation (SHAPE) on the Sonix RP 
scanner, specifically for the measurement of interstitial tumor pressure, will be detailed. 
Requirements 
Probe and frequency 
Based on our previous in vitro results using a water-tank and after looking at the transfer 
function of the Sonix RP we want to implement two different frequency settings for 
SHAPE on the system: 
 8.0 MHz transmit frequency and 4.0 MHz receive frequency and 
 5.4 MHz transmit frequency and 2.7 MHz receive frequency 
As the ultimate goal of this project is to use SHAPE on locally advanced breast cancer in 
human patients we have considered the two linear arrays provided by Ultrasonix, the L9-
4/38 and the L14-5/38 probes. However, we eventually decided on the L9-4/38 probe as 
its bandwidth is more suitable for the two frequency settings selected.  
Dual screen display 
When imaging breast tumors with SHAPE it is essential that the sonographer has a good 
view of both the regular B imaging and the subharmonic mode. Therefore, a dual screen 
display with two images shown simultaneously in real time on the screen is needed; the B 
mode image on one side and the equivalent B mode image with a subharmonic ROI on 
the other side. The sonographer should be able to set the size of the ROI as appropriate, 
with the largest ROI covering the whole image.  
Power optimization 
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There are three different stages of subharmonic generation depending on the acoustic 
pressure: occurrence, growth and saturation. 
Occurrence and saturation are not favorable for 
pressure estimation as the decrease in 
subharmonic response is weak in these stages. 
However, in the growth stage there is a linear 
relationship between the hydrostatic pressure and 
the subharmonic amplitude. The growth stage can 
be identified on a graph of the subharmonic amplitude vs. the acoustic power (see 
example in fig 1). The optimal power setting for SHAPE is the section of the graph with 
the steepest slope (e.g. between 0.3 and 0.4 MPa in fig 1).  In vivo this growth stage 
needs to be located and therefore a power optimization feature or algorithm is needed that 
runs through the acoustic power settings on the scanner and gives the optimal power 
setting (i.e. steepest slope on graph).  
Pulse inversion 
To minimize the effect of the consistent component at approximately 3-5 MHz present 
due to the transfer function of the system and the linear components from the bubbles we 
will implement pulse inversion. Previously, we have set pulse B as an inverse to pulse A 
and set the Accumulator to 2 to implement pulse inversion. However, if possible we 
would like to use six different pulses (i.e. Pulses A, B, C, D, E, F) instead of only two and 
sum them up to implement pulse inversion.  
File Types 
Figure 1 An example s curve picturing 
the three stages of subharmonic 
generation. 
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The file types needed for SHAPE include at least the RF data (.rf) and the B mode image 
(.bpr) offered in the combined B/RF capture on the Sonix RP. 
Summary table 
The following table lists the requirements mentioned in this document and their 
importance level. 
Requirement Importance 
Frequency setting 8/4 MHz  Must have 
Frequency setting 5.4/3.7 MHz Must have 
Dual screen display Must have 
Power optimization Must have 
Modified pulse inversion  Nice to have but not critical 
File type RF Must have 
File type BPR Nice to have but not critical 
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Appendix D: Cell Culturing and Elimination Procedure 
Cell Culturing Procedure – Petri dishes 
 
 
 
 
1) Vacuum out the media from the Petri dishes 
2) Use pipette to inject 2-3 ml of PBS into each Petri dish. Swirl to cover the bottom 
surface of the dish. Leave pipette in PBS flask if no contamination has taken 
place, otherwise or if done using PBS, discard pipette. 
3) Vacuum PBS out of the Petri dishes. 
4) Use pipette to inject 2-3 ml of Trypsin into each Petri dish. Swirl to cover the 
bottom surface of the dish. Leave pipette in Trypsin flask if no contamination has 
taken place, otherwise or if done using Trypsin, discard pipette. 
5) Put Petri dishes into incubator until the cells detach. 
6) Use a pipette to measure an even number (e.g. 10 ml) of media and inject all the 
media measured into the first Petri dish. Now use the same pipette to remove the 
floating cells, Trypsin and media from the Petri dish and inject everything into the 
next Petri dish, repeat until pipette is full or all Petri dishes have been emptied.  
7) Dispense everything from the pipette into a 50 ml centrifuge tube, discard pipette. 
8) Balance tube(s) for centrifuge. 
9) Centrifuge – settings: 4°C, 10 minutes, 1000 rpm, break set to off. 
10) Vacuum out all the media and Trypsin, leaving a small pellet of cells at the 
bottom of the centrifuge tube.  
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11) Flick tube to loosen cells. 
12) Inject (number of Petri dishes x 5 ml – not more than 6 or 7 Petri dishes at a time) 
ml of medium into the tube and redispense/remeasure until no cell pellets are left. 
If there are more than one tube, inject this mix into the next tube as well until no 
cell pellets are left in that tube. 
13) Divide this mix evenly into an appropriate number of centrifuge tubes (reuse the 
tubes used in 7-12) and then add medium to the tubes until the correct amount of 
media/cells is reached (5 ml per Petri dish). 
14) Put Petri dishes into incubator. 
Incubator settings: 37°C and 5.0% CO
2
. 
NB! Spray and wipe down the hood with alcohol before starting and spray and wipe 
down everything that enters the hood either right before or right after entering the hood. 
How to mix medium: 
Take one 500 ml bottle of DMEM 1x. Inject 56 ml of serum (10% of final volume) into 
the DMEM bottle. 
Inject 5.6 ml (1% of final volume) of penicillin streptomycin into the DMEM bottle. 
Swirl to mix. 
Eliminating cells: 
1) Vacuum out all media 
2) Put 20% bleach in the Petri dish 
3) Vacuum out bleach 
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4) Discard of the Petri dish in the proper container 
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Appendix E: Matrigel Preparation 
 
 
 
 
1) Get Matrigel out of freezer and put in a container on ice in the fridge overnight. 
Once Matrigel is ready it will turn from a yellow solid to a red liquid. 
2) Swirl the vial for even dispersion 
3) Spray top with ethanol for sterilization under the hood - keep on ice. 
4) Use a cooled pipette to extract desired volume into cooled tube. 
5) Add equal volume of saline.  
6) Add 5 million cells. 
7) Gently swirl to mix or use pipette if cell pellet has not liquefied. 
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Appendix F: Preparation for Cell Injection and Tumor Scanning 
Injections 
 
 
 
 
 Day before: 
1) Get Matrigel out of freezer and put in a container on ice in the fridge overnight 
(from the ice machine in front of the conference rooms). Once Matrigel is ready it 
will turn from a yellow solid to a red liquid. 
2) Get TB syringes from the 7th floor lab (as many as the injections planned + a few 
extra). 
3) If not done already, contact Animal lab (5-2929) to reserve anesthesia cart, hood 
and rat chamber. 
4) Confirm timing with Jimmy 
 
 Same day: 
1) Bring Matrigel back to 7th floor lab (it needs to be put in a freezer as soon as you 
use it) 
2) Call Jimmy and give him an approximate time about 1 hr before you are ready. 
3) Bring TB needles and permanent marker with you to and Animal lab 
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4) In the animal lab supply room get gauze, alcohol pads and 23 G needles (as many 
as the injections planned + a few extra) from the supply room 
Scanning study 
 Week before: 
1) Email Jennifer in the animal lab the supply list (see below) so that she can have it 
ready for us 
2) Reserve anesthesia cart, rat chamber and hood (if needed) 
 Day before: 
1) Get supplies from lab ready (see below) 
2) Check Stryker pressure monitor (battery etc.) and Sonix RP scanner 
Supply list for Animal Lab 
1) 20+ Angiocatheters (last time we used 24g or 24 3/4 g) - we will need at least 20 
of them for each experiment I would think 
2) 10 x 23 g needles (depending on how many have tumors) 
3) Alcohol prep pads 
4) Bottle of saline 
5) 2-3 scalpel blades 
6) Heating pad 
7) Gauze 
8) Injection plugs 
Supply list from 7
th
 floor lab 
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1) Stryker pressure monitor 
2) Stryker pressure monitor quick set 
3) Sonix RP and L 9-4 transducer 
4) Heating lamp 
5) Stand for heating lamp 
6) Stand for transducer 
7) Transducer covers 
8) Pad with notes for  
9) 20 TB needles 
10) Jimmy’s box 
11) Paclitaxel if applicable 
12) If available gauze, alcohol pads, 23 g needles, saline 
To do after experiments 
1) Copy data to hard drive before moving unit 
2) Put tumor sheets etc in “originals” folder and make copies 
3) Scan sheets 
4) Dropbox sheets and rf and bpr data 
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Appendix G: Animal Procedures for Calibration and Treatment 
Vertabrate Animals 
 
 
 
 
Trial Population 
 A total of 81 athymic, nude, female rats (6 - 8 weeks old) will be studied in this 
project to evaluate the potential for noninvasive pressure estimation with SHAPE.  The 
human breast cancer cell line MDA - MB - 231 will be used as a breast cancer model and 
injected into the mammary fat pad of the rats. First, 21 athymic, nude, female rats, i.e., 3 
groups of 7 animals with one tumor each, one group per timepoint (days 21, 24 and 28) 
will be used for initial calibration studies. After calibrating, 60 nude rats, i.e. 2 groups of 
30 animals (23 treatment and 7 control, timepoints 21, 24 or 28 days) with xenografts 
will be used to establish the ability of SHAPE to monitor therapy responses. 
 The findings of SHAPE will be correlated to the invasive needle based 
measurements of IFP (i.e., the gold standard) using linear regression analysis.  This 
analysis will then be repeated with the treatment and time to establish if any interactions 
occur. Given groups of 7 and 23 animals and assuming the change due to paclitaxel will 
be from 6.9 to 4.4 mmHg (with standard deviations around 1.8 mmHg), the analysis will 
have over 80 % statistical power. 
 In summary, 21 rats (i.e., 3 groups of 7 animals each implanted with one of the 3 
cell lines) will be used for the initial calibration studies.  The remaining 60 nude rat 
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xenografts [(7 untreated + 23 treated rats) x 2 time points = 60 rats] will be used to test 
the ability of SHAPE to monitor therapy responses.   
Trial procedure 
 All rats will be anesthetized with Isoflurane using established methods and placed 
on a warming blanket to maintain body temperature. The cells will be administered to the 
rats in a laminar flow hood.  Subcutaneous injections will be done with a 23 gauge needle 
and then the animal will be returned to the cage, given food and water, monitored and 
maintained for a period of 21, 24 or 28 days.  During this period rats will be observed 
every 2-3 days, and any rat that appears to be in distress due to tumor burden will receive 
a subcutaneous injection of 0.2 mg/kg buprenorphine.  This is in compliance with the 
guidelines for the utilization of rodents in experimental neoplasia, policy no. 104.09. 
 For each rat the SHAPE study will last for no longer than 1 hour and the rats will 
receive Isoflurane as anasthesia for all procedures.  At the end of the study the rats are 
sacrificed by placing them in the standard LAS CO2 chambers with a regulator. 
Animal monitoring plan 
 Following the tumor cell implantation, the rats will be observed 2-3 days/week.  
Any rat that appears to be in distress (see criteria below) due to tumor burden will receive 
a subcutaneous injection of 0.2 mg/kg buprenorphine.  If the euthanasia criteria (see 
criteria below) are met the animals will be sacrificed by placing them in the standard 
LAS CO2 chambers that use tank CO2 and have a regulator.  
Distress criteria 
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Any rat which meets one of the following criteria will be considered to be under distress: 
 Weight loss between 15 and 20 % of baseline weight. 
 Tumor size > 20 mm. 
 Reduced appetite for prolonged periods of time. 
 Reduced lack of movement for prolonged periods of time. 
 Reduced social interactions for prolonged periods of time. 
 The animal will receive a subcutaneous injection of 0.2 mg/kg buprenorphine. 
Euthanasia criteria 
Any rat which meets one of the following criteria will be euthanized: 
 Weight loss exceeding 20 % of baseline weight 
 Tumor size > 25 mm 
 Lack of any movement for prolonged periods of time. 
 Being in distress (see above) for more than 3 days. 
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Appendix H: Algorithm for Calibration and Treatment Studies 
 
 
 
 
Algorithm for extraction of subharmonic at 4 MHz over 1 MHz bandwidth 
function [output]=sh_avg_8(rfdata) 
  
    data=rfdata; 
    loc=find(data(:,1)>3.5 & data(:,1)<4.5); 
    red_data=data(loc,:); 
    output=mean(red_data(:,2)); 
   
Algorithm for execution of data processing 
%Read a single RF file 
[filename, pathname] = uigetfile('*.rf','Select a rf file', 
'MultiSelect','off'); 
cd(pathname); 
Im = RPread(filename); 
rfdata = Im; 
sz = size(rfdata); 
noframes = sz(3); 
  
for l = 1:noframes 
    m = 1; 
    for k = 1:10:(sz(1)-10) 
        for v = 1:sz(2) 
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                rfdata_window = rfdata(k:(k+10), v, l); 
                rfdata_fft(:,:)=fft_signal2(rfdata_window(:,:)); 
                rfdata_fft_log = 20*log(rfdata_fft(:,2)); 
                rfdata_fft_array(:,m,v,l) = rfdata_fft_log; 
                harmonics = [rfdata_fft(:,1) rfdata_fft_log]; 
                subharmonic_avg_8(m,v,l) = sh_avg_8(harmonics); 
        end 
    m = m+1; 
    end 
    %Subharmonic image for Average 8 MHz method 
    sl = num2str(l); 
    figure 
    imagesc(subharmonic_avg_8(:,:,l)) 
    colorbar; 
    caxis([0, 200]) 
    title(strcat('Frame', sl)) 
    saveas(gcf,strcat('Frame',sl,'.fig')) 
    saveas(gcf,strcat('Frame',sl,'.jpg')) 
    close 
end 
  
%Generating MPI image 
[r,c,f]=size(subharmonic_avg_8); 
final_img=subharmonic_avg_8(:,:,1); 
  
disp('Creating the final image after MIP...') 
for t=1:f-1 
    temp_image=subharmonic_avg_8(:,:,t+1); 
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    for i=1:r % Implementation of MIP 
        for j=1:c 
            if final_img(i,j)<temp_image(i,j) 
                final_img(i,j)=temp_image(i,j); 
            else 
            end 
        end 
    end 
%    sprintf('File dealt with: %d',t+1) 
end 
  
% Display the final image after MIP and save it 
figure(1) 
imagesc(final_img) 
colorbar; 
caxis([0, 200]) 
title('MIP image without motion compensation') 
saveas(gcf,strcat('MIP_image','.fig')) 
saveas(gcf,strcat('MIP_image','.jpg')) 
  
%Selecting ROI 
h = imrect; 
pos = h.getPosition; 
xmin = floor(pos(1)); 
ymin = floor(pos(2)); 
width = floor(pos(3)); 
height = floor(pos(4)); 
close  
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xmax = xmin + width; 
ymax = ymin + height; 
xmax 
xmin 
ymax 
ymin 
  
[r,c,f]=size(subharmonic_avg_8(ymin:ymax, xmin:xmax, :)); 
for t=1:f-1 
    allmean(t)=mean(mean(subharmonic_avg_8(ymin:ymax, xmin:xmax,t))); 
end 
  
totalmean = mean(allmean) 
above_thres1 = zeros(r,c); 
above_thres2 = zeros(r,c); 
above_thres3 = zeros(r,c); 
above_thres4 = zeros(r,c); 
th1 = 1; 
th2 = 1.15; 
th3 = 1.30; 
  
  
%threshold 1 100% of mean 
for t=1:f-1 
    temp_img=subharmonic_avg_8(ymin:ymax, xmin:xmax,t+1); 
    for i=1:r  
        for j=1:c 
            if temp_img(i,j)<=th1*totalmean 
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                temp_img(i,j)=totalmean; 
            else 
                above_thres1(i,j) = temp_img(i,j); 
            end 
        end 
    end 
end 
 figure(1) 
imagesc(temp_img) 
colorbar; 
caxis([0, 200]) 
title('ROI with threshold 100%') 
saveas(gcf,strcat('threshold100','.fig')) 
saveas(gcf,strcat('threshold100','.jpg')) 
  
num1 = sum(above_thres1~=0); %number of nonzero elements 
MeanShape1 = sum(above_thres1)/num1 %Average value above threshold 
  
%threshold 2 115% of mean 
for t=1:f-1 
    temp_img=subharmonic_avg_8(ymin:ymax, xmin:xmax,t+1); 
    for i=1:r  
        for j=1:c 
            if temp_img(i,j)<=th2*totalmean 
                temp_img(i,j)=totalmean; 
            else 
                above_thres2(i,j) = temp_img(i,j); 
            end 
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        end 
    end 
end 
 figure(2) 
imagesc(temp_img) 
colorbar; 
caxis([0, 200]) 
title('ROI with threshold 115%') 
saveas(gcf,strcat('threshold115','.fig')) 
saveas(gcf,strcat('threshold115','.jpg')) 
  
num2 = sum(above_thres2~=0); %number of nonzero elements 
MeanShape2 = sum(above_thres2)/num2 %Average value above threshold 
  
%threshold 3 130% of mean 
for t=1:f-1 
    temp_img=subharmonic_avg_8(ymin:ymax, xmin:xmax,t+1); 
    for i=1:r  
        for j=1:c 
            if temp_img(i,j)<=th3*totalmean 
                temp_img(i,j)=totalmean; 
            else 
                above_thres3(i,j) = temp_img(i,j); 
            end 
        end 
    end 
end 
 figure(3) 
171 
imagesc(temp_img) 
colorbar; 
caxis([0, 200]) 
title('ROI with threshold 130%') 
saveas(gcf,strcat('threshold130','.fig')) 
saveas(gcf,strcat('threshold130','.jpg')) 
  
num3 = sum(above_thres3~=0); %number of nonzero elements 
MeanShape3 = sum(above_thres3)/num3 %Average value above threshold 
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Appendix I: Comparison after Removing IFP Data Points with High Variability 
 
 
 
 
 For both calibration and treatment a linear regression analysis was performed 
after removing data points where the ratio of standard deviation to the mean (standard 
deviation/mean) of three data points was larger than 50% and where it was larger than 
100%. 
Calibration: 
Data points where standard deviation of IFP/mean of IFP > 50% removed: 
 
Figure 1Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 50% have been eliminated. 
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Figure 2 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 50% have been eliminated 
 
Figure 3Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 50% have been eliminated 
Data points where standard deviation of IFP/mean of IFP > 100% removed: 
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y = -0.7904x + 142.62 
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Figure 4 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 100% have been eliminated 
 
Figure 5 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 100% have been eliminated 
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Figure 6 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 100% have been eliminated 
Treatment: 
Data points where standard deviation of IFP/mean of IFP > 50% removed: 
 
Figure 7 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 50% have been eliminated 
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Figure 8 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 50% have been eliminated 
 
Figure 9 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this case 
data points with a IFP standard deviation / IFP mean larger than 50% have been eliminated 
Data points where standard deviation of IFP/mean of IFP > 100% removed: 
y = -0.778x + 126.7 
r = -0.69, p < 0.01, n = 75  
0
20
40
60
80
100
120
140
160
-10 0 10 20 30 40
Su
b
h
ar
m
o
n
ic
 A
m
p
lit
u
d
e
 [
d
B
] 
Interstitial Fluid Pressure [mmHg] 
115% 
y = -0.8913x + 141.2 
r = -0.71, p < 0.01, n = 75  
0
20
40
60
80
100
120
140
160
180
200
-10 0 10 20 30 40
Su
b
h
ar
m
o
n
ic
 A
m
p
lit
u
d
e
 [
d
B
] 
Interstitial Fluid Pressue [mmHg] 
130% 
177 
 
Figure 10 Subharmonic amplitude results compared to the pressure monitor at a 100% threshold. In this 
case data points with a IFP standard deviation / IFP mean larger than 100% have been eliminated 
 
Figure 11 Subharmonic amplitude results compared to the pressure monitor at a 115% threshold. In this 
case data points with a IFP standard deviation / IFP mean larger than 100% have been eliminated 
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Figure 12 Subharmonic amplitude results compared to the pressure monitor at a 130% threshold. In this 
case data points with a IFP standard deviation / IFP mean larger than 100% have been eliminated 
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